

Vitamin D and assisted reproductive treatment outcome: A systematic review and meta-analysis

Chu, Justin; Gallos, Ioannis; Tobias, Aurelio; Tan, Bee; Eapen, Abey; Coomarasamy, Aravinthan

DOI:

[10.1093/humrep/dex326](https://doi.org/10.1093/humrep/dex326)

Document Version

Peer reviewed version

Citation for published version (Harvard):

Chu, J, Gallos, I, Tobias, A, Tan, B, Eapen, A & Coomarasamy, A 2017, 'Vitamin D and assisted reproductive treatment outcome: A systematic review and meta-analysis', *Human Reproduction*, vol. 33, no. 1, pp. 65-80. <https://doi.org/10.1093/humrep/dex326>

[Link to publication on Research at Birmingham portal](#)

Publisher Rights Statement:

Checked for eligibility: 09/11/2017

This is a pre-copyedited, author-produced version of an article accepted for publication in *Human Reproduction* following peer review. The version of record [Justin Chu, Ioannis Gallos, Aurelio Tobias, Bee Tan, Abey Eapen, Arri Coomarasamy; Vitamin D and assisted reproductive treatment outcome: a systematic review and meta-analysis, *Human Reproduction*, Volume 33, Issue 1, 1 January 2018, Pages 65–80] is available online at: <https://academic.oup.com/humrep/article/33/1/65/4582928>
<https://doi.org/10.1093/humrep/dex326>

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.



Draft Manuscript For Review. Reviewers should submit their review at <http://mc.manuscriptcentral.com/humrep>

Vitamin D and assisted reproductive treatment outcome: A systematic review and meta-analysis

Journal:	<i>Human Reproduction</i>
Manuscript ID	HUMREP-17-0337.R2
Manuscript Type:	Meta-Analysis
Date Submitted by the Author:	26-Sep-2017
Complete List of Authors:	Chu, Justin; University of Birmingham, Tommy's National Centre for Miscarriage Research, Institute of Metabolism and Systems Research; Birmingham Women's and Children's NHS Foundation Trust Gallos, Ioannis; University of Birmingham, Tommy's National Centre for Miscarriage Research, Institute of Metabolism and Systems Research; Birmingham Women's and Children's NHS Foundation Trust Tobias, Aurelio; University of Birmingham, Tommy's National Centre for Miscarriage Research, Institute of Metabolism and Systems Research; Spanish Council for Scientific Research, Institute of Environmental Assessment and Water Research Tan, Bee; Heart of England NHS Foundation Trust; University of Warwick, Reproductive Health Eapen, Abey; University of Birmingham, Institute of Metabolism and Systems Research; Birmingham Women's and Children's NHS Foundation Trust Coomarasamy, Arri; University of Birmingham, Institute of Metabolism and Systems Research; Birmingham Women's and Children's NHS Foundation Trust
Keywords:	Vitamin D, IMPLANTATION, Assisted reproductive treatments, In Vitro Fertilisation, ENDOMETRIAL RECEPTIVITY
Subject Section:	Infertility

SCHOLARONE™
Manuscripts

1 Vitamin D and assisted reproductive treatment outcome: A systematic review and meta-analysis

2

3 **RUNNING TITLE**

4 Vitamin D and assisted reproductive treatment outcome

5

6 **AUTHORS**

7 Justin Chu^{1,2}, Ioannis Gallos^{1,2*}, Aurelio Tobias^{1,3}, Bee Tan^{4,5}, Abey Eapen^{1,2} and Arri Coomarasamy^{1,2}

8

9

10 ¹ Tommy's National Centre for Miscarriage Research, Institute of Metabolism and Systems Research,

11 University of Birmingham, Birmingham, B15 2TT, UK

12 ²Birmingham Women's and Children's NHS Foundation Trust, Mindelsohn Way, Birmingham, B15

13 2TG, UK

14 ³Spanish Council for Scientific Research, Institute of Environmental Assessment and Water Research,

15 Barcelona, Spain

16 ⁴Heartlands Hospital, Heart of England NHS Foundation Trust, Bordesley Green East, Birmingham B9

17 5SS, UK

18 ⁵Reproductive health, Warwick University, Coventry, CV4 7AL, UK

19

20 ***CORRESPONDENCE ADDRESS:** Email i.d.gallos@bham.ac.uk, Birmingham Women's Foundation

21 NHS Trust, Edgbaston, B15 2TG

22

23

24 **ABSTRACT**

25

26 **Study question:** Is serum vitamin D associated with live birth rates in women undergoing assisted
27 reproductive treatment?

28

29 **Summary answer:** Women undergoing assisted reproductive treatment who are replete in vitamin D
30 have a higher live birth rate than women who are vitamin D deficient or insufficient.

31

32 **What is known already:** Vitamin D deficiency has been associated with an increased risk of
33 abnormal pregnancy implantation as well as obstetric complications such as pre-eclampsia and fetal
34 growth restriction. However, the effect of vitamin D on conception and early pregnancy outcomes in
35 couples undergoing assisted reproductive treatment is poorly understood.

36

37 **Study design, size, duration:** A systematic review and meta-analysis of 11 published cohort studies
38 (including 2700 women) investigating the association between vitamin D and assisted reproductive
39 treatment outcomes.

40

41 **Participants/materials, settings, methods:** Literature searches were conducted to retrieve studies
42 which reported on the association between vitamin D and assisted reproductive treatment
43 outcomes. Databases searched included MEDLINE, EMBASE, Cochrane Central Register of Controlled
44 Trials and CINAHL. Eleven studies matched the inclusion criteria.

45

46 **Main results and the role of chance:** Live birth was reported in seven of the included studies
47 (including 2026 patients). Live birth was found to be more likely in women replete in vitamin D when
48 compared to women with deficient or insufficient vitamin D status (OR 1.33 [1.08 to 1.65]). Five
49 studies (including 1700 patients) found that women replete in vitamin D were more likely to achieve

50 a positive pregnancy test than women deficient or insufficient in vitamin D (OR 1.34 ([1.04 to 1.73]).
51 All 11 of the included studies (including 2700 patients) reported clinical pregnancy as an outcome.
52 Clinical pregnancy was found to be more likely in women replete in vitamin D (OR 1.46[1.05 to
53 2.02]). Six studies (including 1635 patients) reported miscarriage by vitamin D concentrations. There
54 was no association found between miscarriage and vitamin D concentrations (OR 1.12 [0.81 to 1.54].
55 The included studies scored well on the Newcastle Ottawa quality assessment scale.

56

57 **Limitations, reasons for caution:** Although strict inclusion criteria were used in the conduct of the
58 systematic review, the included studies are heterogeneous in population characteristics and fertility
59 treatment protocols.

60

61 **Wider implications of the findings:** The findings of this systematic review show that there is an
62 association between vitamin D status and reproductive treatment outcomes achieved in women
63 undergoing assisted reproductive treatment. Our results show that vitamin D deficiency and
64 insufficiency could be important conditions to treat in women considering assisted reproductive
65 treatments. A randomised controlled trial to investigate the benefits of vitamin D deficiency
66 treatment should be considered to test this hypothesis.

67

68 **Study funding/competing interests:** No external funding was either sought or obtained for this
69 study. The authors have no competing interests to declare.

70

71 **Registration number:** N/A

72

73 **Key words:** Vitamin D / Implantation / Assisted reproductive treatments / In vitro fertilisation /
74 Endometrial receptivity

75

76 **INTRODUCTION**

77 Infertility causes great psychological and sometimes physical distress to one in seven couples
78 (National Institute for Health and Care Excellence 2013). In the United Kingdom (UK), in 2014, 52,288
79 women underwent 67,708 in vitro fertilization (IVF) treatment cycles (Human Fertility Embryology
80 Authority 2016). The overall success rate of these assisted reproductive treatments (ART) was 36.3%
81 (Human Fertility Embryology Authority 2016). Since the availability of ART treatment has become
82 more widespread, success rates have gradually increased (Grady et al. 2012). This has largely been
83 due to the research conducted in embryology, which has enhanced our abilities to select and
84 transfer the embryo with the highest pregnancy potential. More recently, the rate of improvement
85 in success rates has slowed (Busso et al. 2006). There remains ample room for improvement in
86 fertility treatments to maximize the chances of achieving pregnancy. Much of this lies in improving
87 the likelihood for implantation of the selected embryo that is transferred in to the uterus (Macklon
88 et al. 2002).

89

90 There has been recent interest in the role of vitamin D in reproductive physiology as findings have
91 shown that as much as 20 to 52% of women of reproductive age are deficient in vitamin D (Gordon
92 et al. 2004; Sullivan et al. 2005; Tangpricha et al. 2002). It is postulated that vitamin D is important in
93 the process of pregnancy implantation as vitamin D enzymes and receptors have been found in the
94 endometrium (Lerchbaum & Rabe 2014). Additionally, vitamin D deficiency has been found to cause
95 decreased fertility capacity, hypogonadism and uterine hypoplasia in animal studies (Halloran &
96 DeLuca 1980; Kinuta et al. 2000; Yoshizawa et al. 1997; Panda et al. 2001). In humans, the
97 importance of vitamin D in placental function is the most studied aspect of vitamin D in reproduction
98 (Aghajafari et al. 2013). Specifically, vitamin D deficiency has been linked to poor placentation,
99 leading to hypertensive disorders of pregnancy (pre-eclampsia and pregnancy induced hypertension)
100 and fetal growth restriction (Aghajafari et al. 2013). More recently, it has been proposed that
101 vitamin D may be a regulator of initial embryo implantation and that improper implantation, due to

102 vitamin D deficiency, is the cause of poor placentation (Bodnar et al. 2007; Baker et al. 2010;
103 Robinson et al. 2011).

104

105 Our main source of vitamin D, a fat-soluble steroid hormone, is from sunlight. Only a small amount is
106 obtained from our diet. The majority of the body's vitamin D is in the form of vitamin D₃
107 (cholecalciferol), which is photo-chemically synthesized in the skin (Holick 2007).

108

109 Vitamin D concentrations are usually measured by assay of serum 25-hydroxy vitamin D₃ status.
110 Experts in nutrition have suggested that people are at risk of the detrimental effects of vitamin D
111 deficiency at serum 25-hydroxy vitamin D₃ concentrations of less than 50 nmol/L (less than
112 20ng/mL). A concentration of 50 to 75 nmol/L (21 to 29 ng/mL) is considered insufficient and greater
113 than 75nmol/L (greater than 30 ng/ml) is considered vitamin D replete. These vitamin D
114 concentration cut-offs are those adopted by the Endocrine Society (Holick et al. 2011). Differing
115 vitamin D concentration cut-offs have also been proposed by the Institute of Medicine (IOM), who
116 suggest that vitamin D deficiency is when serum 25-hydroxy vitamin D₃ concentrations are less than
117 30 nmol/L (less than 12ng/mL), vitamin D insufficiency is when serum 25-hydroxy vitamin D₃
118 concentrations are between 30 nmol/L and 50nmol/L (between 12 and 20ng/mL), and that serum
119 25-hydroxy vitamin D₃ concentrations greater than 50nmol/L (greater than 20ng/mL) are considered
120 replete (Ross et al. 2011). There is agreement that serum concentrations greater than 374 nmol/L
121 (greater than 150 ng/mL) are associated with toxicity and adverse effects (Tangpricha et al. 2002;
122 Heaney 2008; Stephanou et al. 1994; Daftary & Taylor 2006).

123

124 The biological plausibility that vitamin D plays an important role in implantation has led research
125 groups to investigate the importance of vitamin D in patients undergoing ART. Some studies have
126 found that replete concentrations of vitamin D lead to an increase in clinical pregnancy and live birth
127 rates (Rudick et al. 2014; Ozkan et al. 2010; Rudick et al. 2012; Garbedian et al. 2013; Paffoni et al.

128 2014). However, others have found conflicting evidence suggesting that vitamin D has no effect on
129 the outcome of ART (Anifandis et al. 2010; Aleyasin et al. 2011; Firouzabadi et al. 2014; Fabris et al.
130 2014; Franasiak et al. 2015). The aim of our review was to investigate the association between
131 vitamin D status and reproductive outcomes by meta-analysis of the ART outcomes of published
132 cohort studies to summarise the available evidence.

133 **METHODS**

134 **Inclusion Criteria**

135 The study was designed a priori with inclusion of primary articles that studied women undergoing
136 any form of ART (IVF, ICSI and frozen embryo transfer [FET]) who had their vitamin D status checked.
137 This could either be through blood serum or follicular fluid assay. The primary outcome was live
138 birth rates according to vitamin D status. Secondary outcomes included biochemical pregnancy
139 rates, and clinical pregnancy rates.

140

141 **Literature search**

142 MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials and CINAHL (from inception to
143 April 2017) were searched. The search strategy used the following key words and/or medical subject
144 heading (MeSH) terms: pregnancy, *in vitro* fertilization, intracytoplasmic sperm injection, assisted
145 reproductive techniques and vitamin D. The full electronic search strategy is provided in
146 Supplementary Table S1. References of all included primary and review articles were examined to
147 identify relevant articles not captured by the electronic searches. No language restrictions were
148 applied in any of the searches or study selection.

149

150 Study selection

151 Criteria for inclusion in the study were established prior to the literature search. Two independent
152 reviewers (J.C. and B.T.) carried out study selection. First, the independent reviewers scrutinized the
153 titles and abstracts of the electronic searches. Each title and abstract were included or excluded
154 independently according to the predefined inclusion criteria; any disagreements regarding inclusion
155 were resolved by a further reviewer (I.D.G). The full manuscripts of the titles and abstracts
156 considered to be relevant for inclusion were obtained. When there was a duplicate publication, the
157 most recent and complete version was selected and included. Studies that did not explicitly report
158 results from assisted reproductive treatments according to vitamin D groups (deficient, insufficient
159 and replete) according to Endocrine Society guidelines were excluded.

160

161 The same two independent reviewers (J.C. and B.T.) extracted the outcome data from the included
162 studies.

163

164 Study quality assessment

165 Two reviewers (J.C and B.T.) used the Newcastle-Ottawa Quality Assessment Scales for observational
166 studies to complete a quality assessment of the included manuscripts(Wells et al. 2011). The
167 Newcastle-Ottawa scale ranges from zero to nine, awarding one star for all categories (case-cohort
168 representative, ascertainment of exposure, outcome negative at commencement of study, outcome
169 assessment, duration of follow up and adequacy of follow up) except comparability by design or
170 analysis where two stars can be awarded. An arbitrary score was allocated assuming that all items
171 have equal weighting. This was used to give a quantitative appraisal of overall quality of the
172 individual studies. Each study received a score from each of the reviewers.

173

174 Publication Bias

175 Assessment for publication bias in the included studies for the outcome of clinical pregnancy was
176 performed using Harbord's modified test for small study effects to assess for funnel plot asymmetry
177 ((Harbord et al. 2006).

178 Statistical analysis

179 Live birth, biochemical pregnancy, clinical pregnancy and miscarriage rates were extracted from
180 each of the included studies according to vitamin D strata. The log of the ratio and its corresponding
181 standard error for each study was computed. Meta-analysis using inverse-variance weighting was
182 performed to calculate the random-effects summary estimates. The square root of this number is
183 the estimated standard deviation of the underlying effects across studies. Because we had relative
184 measures of effect, the confidence intervals were centered on the natural logarithm of the pooled
185 estimate and the limits exponentiated to obtain an interval on the ratio scale. Forest plots were
186 created for each outcome, showing individual study proportions with confidence intervals (CIs) and
187 the overall DerSimonian-Laird pooled estimate according to vitamin D status. Heterogeneity of the
188 treatment effects was assessed graphically with forest plots and statistically analyzed using the χ^2
189 test. Statistical analyses were performed using Stata 12.1 (StataCorp, College Station, TX).

190 RESULTS

191 The PRISMA flow diagram (Liberati et al. 2009; Moher et al. 2009) of the review process is presented
192 in Fig. 1. The search strategy yielded 4615 citations, of which 4505 citations were excluded as it was
193 clear from scrutinizing the title and abstract that they did not fulfil the selection criteria. Full
194 manuscripts of 110 articles were obtained. A total of 99 of these publications were excluded because
195 35 were reviews, 24 articles did not specify outcomes from ART, 17 articles did not specify
196 investigating vitamin D, seven articles were conference abstracts or studies where there was no
197 extractable data (Farzadi et al. 2015; Neville et al. 2016) (as they provided mean vitamin D
198 concentrations of groups of women achieving clinical pregnancy and those that did not) , five articles

199 reported male infertility, four articles were animal studies, three were letters, two were duplicates,
200 and one was a study protocol. Therefore, the total number of observational studies included in the
201 review was 11.

202

203 **Study characteristics**

204 Study characteristics of the 11 included studies are presented in Table I. None of the included
205 studies declared any conflicts of interest. The included studies varied in publication date between
206 2010 and 2015. All 11 included studies were cohort studies; six were retrospective and five were
207 prospective in design. Sample sizes varied between 84 women to 517 women. Nine of the 11
208 included studies reported the ages of their study population. Seven studies had a mean age of below
209 37 years and two had a higher mean age of 40.5 and 40.9 years. Eight included studies used serum
210 measurement of vitamin D, two used both follicular fluid and serum vitamin D (finding that there
211 was high correlation between the follicular fluid vitamin D and serum vitamin D in their participants),
212 and one study used follicular fluid alone. Of the 11 included studies, nine studies reported ART
213 where women had used autologous oocytes. Two reported results from women who were donor
214 egg recipients. One study used pre-implantation genetic screening to ensure that patients had
215 karyotypically normal embryos transferred. One study chose to only study women that underwent a
216 single blastocyst transfer. All of the 11 included studies assayed 25-hydroxy-vitamin D. Four of the
217 included studies assessed vitamin D before the commencement of the treatment cycle, three
218 assessed vitamin D at the time of ovulation trigger, three assessed vitamin D at the time of oocyte
219 retrieval, and one study assessed vitamin D just before oocyte retrieval. All of the 11 included
220 studies used the Endocrine Society classification of vitamin D status (less than 50nmol/L deficient,
221 50-75nmol/L insufficient, and greater than 75nmol/L replete). Six of the included studies provided
222 adjusted odds ratios, adjusting for potential confounding factors. Of these six studies, only four
223 provided adequate detail for potential meta-analysis of adjusted odds ratios. However, two of these

224 studies had adjusted for vitamin D concentration and another two studies had used differing
225 referent groups to obtain adjusted odds ratios.

226

227 A funnel plot to test for asymmetry did not find substantial evidence of publication bias ($p=0.933$)
228 (Supplementary Figure S1).

229

230 All studies scored well using the Newcastle-Ottawa Quality Assessment achieving a score between 7
231 and 9 (Table II).

232

233

234 **Vitamin D deficiency prevalence**

235 Our review found a high prevalence of vitamin D deficiency. The meta-analysed prevalence for
236 vitamin D deficiency, insufficiency and replete were 34.6% (95% CI 32.0 to 37.4), 45.3% (95% CI 42.4
237 to 48.5) and 25.7% (95% CI 23.4 to 28.2%) respectively.

238

239 **Live birth**

240 Seven studies (2026 participants) reported the live births achieved by women when categorized by
241 vitamin D (Fig. 2). Meta-analysis of the data from these studies showed that women who are vitamin
242 D replete have a higher chance of achieving a live birth from ART when compared with women with
243 vitamin D deficiency or insufficiency. The odds ratio was 1.33 (1.08 to 1.65). The meta-analysis had
244 low statistical heterogeneity with an I^2 value of 5.0% ($p=0.39$).

245

246 **Biochemical pregnancy**

247 Five studies (1700 participants) reported the number of women that achieved a positive pregnancy
248 test approximately two weeks after embryo transfer for the three vitamin D categories. The odds of

249 biochemical pregnancy in the vitamin D deficient and insufficient population versus the vitamin D
250 replete population are presented in Fig. 3. Meta-analysis of these five cohort studies showed a
251 greater chance of pregnancy in the vitamin D replete group when compared with the vitamin D
252 deficient and insufficient groups with an odds ratio of 1.34 (1.04 to 1.73). There was a low level of
253 statistical heterogeneity with an I^2 value of 21.0% ($p=0.28$).

254

255 **Clinical pregnancy**

256 All 11 studies (2700 participants) reported on clinical pregnancy rate (the presence of fetal heart
257 approximately five weeks after embryo transfer) as an outcome (Fig. 4). Pooling of the clinical
258 pregnancy outcomes from the 11 studies showed an improved chance of clinical pregnancy in the
259 vitamin D replete population when compared with the vitamin D deficient and insufficient
260 population. The vitamin D replete group was more likely to achieve clinical pregnancy when
261 compared with the vitamin D deficient and insufficient groups with an odds ratio of 1.46 (1.05 to
262 2.02). The I^2 value for this meta-analysis was 61.0% suggesting a moderate level of statistical
263 heterogeneity ($p=0.02$).

264

265 Data could be extracted from nine of the included studies (2082 patients) to compare the chances of
266 clinical pregnancy by using the IOM definitions of vitamin D status (vitamin D concentrations of less
267 than 50nmol/L considered as deficient or insufficient and vitamin D concentrations of more than
268 50nmol/L considered replete). Pooling of the clinical pregnancy rates from these nine studies also
269 showed that women with a vitamin D concentration of greater than 50nmol/L were more likely to
270 achieve a clinical pregnancy when compared to women with a vitamin D concentration of below
271 50nmol/L with an odds ratio of 1.38 (1.04 to 1.83) (Supplementary Figure S2).

272

273 Clinical pregnancy according to source of oocyte used

274 The 11 included studies were divided into two groups according to the source of the oocyte
275 (autologous or donor) used to form the embryo for transfer (Fig. 5). Nine studies (including 2334
276 patients) reported fertility outcomes in infertile women receiving an autologous oocyte embryo.
277 Clinical pregnancy was found to be more likely in women who were vitamin D replete who received
278 an autologous oocyte embryo (OR 1.39 [1.00 to 1.93]). The I^2 value for this meta-analysis was 56.0%
279 suggesting a moderate level of statistical heterogeneity ($p=0.02$).

280

281 In the two studies (including 366 patients) where women received a donor oocyte embryo, no
282 significant difference was found when comparing the clinical pregnancy in women receiving a donor
283 oocyte embryo who were vitamin D replete when compared to women who were vitamin D
284 deficient or insufficient (OR 2.02 [0.44 to 9.26]). The I^2 value for this meta-analysis was 85.0%
285 suggesting a considerable level of statistical heterogeneity ($p=0.009$).

286

287 Miscarriage

288 Six studies (1635 participants) reported on the outcome of miscarriage (Fig. 6). When the data from
289 these six studies are pooled, the chance of miscarriage in the vitamin D replete women is similar to
290 that of vitamin D deficient and insufficient women with an odds ratio of 1.12 (0.81 to 1.54). There
291 was a low level of statistical heterogeneity denoted by an I^2 value of 0.0% ($p=0.76$).

292

293 DISCUSSION

294 This systematic review including 11 studies suggests that the chances of achieving a live birth, a
295 positive pregnancy test and clinical pregnancy after ART are higher in women who are vitamin D
296 replete when compared to those who are vitamin D deficient or insufficient. Miscarriage does not
297 appear to be associated with vitamin D status.

298

299 Our analysis was strengthened by a number of factors. A comprehensive search strategy was used,
300 employing relevant research databases. Additionally, a valid data synthesis method was
301 implemented and no language restrictions were applied. The Newcastle-Ottawa Quality Assessment
302 Scale was used to assess the quality of the included studies. The assessment of all studies scored
303 well on this scale, suggesting low risk of bias.

304

305 There are also weaknesses in our analysis, which mainly stem from the clinical heterogeneity of the
306 publications that were included. Some degree of heterogeneity is to be expected due to the
307 different geographical locations that the individual cohort studies have been conducted, leading to
308 differing population characteristics and ART protocols used. However, this is not necessarily a
309 disadvantage as some degree of clinical heterogeneity can increase the generalisability of the
310 findings to wider infertility populations.

311

312 Ideally, when meta-analysing cohort studies, the adjusted odds ratios (where provided) should be
313 meta-analysed. However, in our included studies it was infrequent for the included primary studies
314 to have provided sufficient detail of their adjusted analysis for known confounding factors such as
315 age and BMI. Therefore, we were unable to perform a meta-analysis of adjusted odds ratios.

316

317 One source of clinical heterogeneity between the included studies is in the timing of vitamin D
318 assessment. Some of the studies measured their participants' vitamin D status before the start of
319 ART, whereas others measured vitamin D at the time of oocyte retrieval. Vitamin D status is known
320 to not fluctuate over time unless vitamin D deficiency or insufficiency is actually treated (Anagnostis
321 et al. 2013). Therefore, the importance of the difference in timing of the vitamin D assessment
322 reduces.

323

324 There were also differences in the bio-fluid used to assess vitamin D status amongst the included
325 studies. Three of the included studies measured vitamin D in the follicular fluid aspirated at the time
326 of oocyte retrieval. The remaining studies used blood serum for vitamin D measurement.
327 Reassuringly, a number of previously published studies have found that assays of vitamin D in
328 follicular fluid or blood serum produce results that are highly correlative (Aleyasin et al. 2011;
329 Anifandis et al. 2010; Firouzabadi et al. 2014; Ozkan et al. 2010). Serum vitamin D would be
330 measured more conveniently in women undergoing ART and could be tested before the start of
331 treatment to allow time for correction of deficiency.

332

333 We found that the likelihood of achieving a positive pregnancy test after embryo transfer was higher
334 in women who were replete in vitamin D. This would support the hypothesis that vitamin D affects
335 embryo implantation. Two of the included studies have tried to investigate the effect of vitamin D on
336 implantation further by only including women undergoing oocyte recipient treatment cycles (Fabris
337 et al. 2014; Rudick et al. 2014). Isolating recipients of donor oocyte embryos aims to reduce the
338 impact of oocyte quality on reproductive outcomes. Donated oocytes would be sourced from
339 younger women with higher quality oocytes and therefore implantation can be investigated more
340 accurately. Meta-analysis of the clinical pregnancy data from these two studies (including 366
341 patients) did not show a statistically significant difference in chance of clinical pregnancy between
342 the vitamin D replete and vitamin D deficient or insufficient populations. However, the data may
343 suggest a higher chance of clinical pregnancy in the vitamin D replete group. It is likely that the
344 failure to reach statistical significance is due to the low number of participants in view of the wide
345 confidence intervals (Schünemann et al. 2011). Removal of these two studies from the overall
346 analysis did not alter the overall association between vitamin D concentration and clinical
347 pregnancy.

348

349 Seasonal variations in conception rates have been established (Rojansky et al. 1992) with higher
350 conception rates found in the Summer and Autumn. Although many hypotheses have been
351 postulated to explain this phenomenon (e.g. reduced ovulation rates and poorer sperm quality in
352 darker months) the exact mechanism behind this has not been explained. It is possible that an
353 increase in sun exposure and greater sunlight luminosity increases the body's store of vitamin D,
354 thereby yielding higher conception rates in Summer and Autumn.

355

356 Although the debate regarding the importance of vitamin D and seasonal variation in reproductive
357 health continues, its impact on immunomodulation within the endometrium with a resultant
358 reduction in active inflammatory cytokines is now well understood (Holick 2007). The expression of
359 vitamin D receptors at the level of the endometrium and the role of vitamin D in the transcription of
360 HOX10A gene (found to be of key importance in implantation) suggest that the immunomodulatory
361 effects of vitamin D may have a direct impact on implantation and therefore the likelihood of
362 reproductive treatment success (Evans et al. 2004).

363

364 Ethnicity has also been found to be a prognostic marker for IVF treatment success, with women of
365 Asian and Black ethnic origins having worse reproductive outcomes (Dhillon et al. 2016). One
366 possible explanation for this finding could be lower serum vitamin D concentrations in these ethnic
367 groups or differences in the vitamin D receptor gene polymorphisms (Ingles 2007; John et al. 2007).

368

369 Our review demonstrates that replete vitamin D status is associated with greater chances of ART
370 success. This could be via the actions of vitamin D on the endometrium promoting embryo
371 implantation or as a surrogate marker for general well-being (Lerchbaum & Rabe 2014). Vitamin D
372 serum testing is relatively cheap and widely available and its treatment is not costly. Therefore it
373 may be beneficial to diagnose and treat vitamin D deficiency in women planning ART to optimize
374 their pregnancy outcomes. Correction of vitamin D deficiency in these patients would also be of

375 benefit during pregnancy, as replete vitamin D concentrations have been found to reduce the risk of
376 obstetric complications such as gestational diabetes (Wang et al. 2012; Zhang et al. 2015), pre-
377 eclampsia (Moon et al. 2015; De-Regil et al. 2012; Wei 2014), and fetal growth restriction (Conde-
378 Agudelo et al. 2013; Khalessi et al. 2015). To further investigate the value of treatment of vitamin D
379 deficiency in the infertile population an interventional trial would be necessary.

380 **Acknowledgments**

381 The authors would like to acknowledge Derick Yates (Birmingham Women's and Children's NHS
382 Foundation Trust) who helped design the search strategy for the systematic review and meta-
383 analysis.

384

385 **Authors' roles**

386 JC and AC were responsible for defining the research question. JC designed the strategy for literature
387 search. JC and BT assessed eligibility of studies for inclusion to the systematic review. Statistical
388 analyses were performed by AT and IDG. AE assisted in the design of the systematic review search
389 strategy and in manuscript preparation. JC wrote the first draft of the manuscript and is its
390 guarantor. All authors revised it critically for important intellectual content and gave final approval
391 of the version to be published.

392

393 **Funding**

394 No external funding was either sought or obtained for this study.

395

396 **Conflicts of interest**

397 None to declare

398

399 **References**

- 400 Aghajafari, F. et al., 2013. Association between maternal serum 25-hydroxyvitamin D level and
401 pregnancy and neonatal outcomes: systematic review and meta-analysis of observational
402 studies. *BMJ*, 346, p.f1169. Available at:
403 <http://www.ncbi.nlm.nih.gov/pubmed/23533188>
404 <http://www.bmj.com/content/bmj/346/bmj.f1169.full.pdf>.
- 405 Aleyasin, A. et al., 2011. Predictive value of the level of vitamin D in follicular fluid on the outcome of
406 assisted reproductive technology. *Eur J Obstet Gynecol Reprod Biol*, 159(1), pp.132–137.
- 407 Anagnostis, P., Karras, S. & Goulis, D.G., 2013. Vitamin D in human reproduction: A narrative review.
408 *International Journal of Clinical Practice*, 67(3), pp.225–235.
- 409 Anifandis, G.M. et al., 2010. Prognostic value of follicular fluid 25-OH vitamin D and glucose levels in
410 the IVF outcome. *Reproductive biology and endocrinology : RB&E*, 8, p.91.
- 411 Baker, A.M. et al., 2010. A Nested Case-Control Study of Midgestation Vitamin D Deficiency and Risk
412 of Severe Preeclampsia. *The Journal of Clinical Endocrinology & Metabolism*, 95(11), pp.5105–
413 5109. Available at: <http://press.endocrine.org/doi/abs/10.1210/jc.2010-0996>.
- 414 Bodnar, L.M. et al., 2007. Maternal vitamin D deficiency increases the risk of preeclampsia. *The*
415 *Journal of clinical endocrinology and metabolism*, 92(9), pp.3517–22. Available at:
416 <http://press.endocrine.org/doi/full/10.1210/jc.2007-0718>.
- 417 Busso, C.E. et al., 2006. Implantation in IVF. *International Surgery*, 91(5 SUPPL.).
- 418 Conde-Agudelo, A. et al., 2013. Novel biomarkers for predicting intrauterine growth restriction: A
419 systematic review and meta-analysis. *BJOG: An International Journal of Obstetrics and*
420 *Gynaecology*, 120(6), pp.681–694.
- 421 Daftary, G.S. & Taylor, H.S., 2006. Endocrine regulation of HOX genes. *Endocrine Reviews*, 27(4),
422 pp.331–355.
- 423 De-Regil, L.M. et al., 2012. Vitamin D supplementation for women during pregnancy. *Cochrane*
424 *database of systematic reviews (Online)*, 2(2), p.CD008873. Available at:

- 425 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008873.pub2/pdf/standard\nhttp://>
426 www.ncbi.nlm.nih.gov/pubmed/22336854.
- 427 Dhillon, R.K. et al., 2016. Predicting the chance of live birth for women undergoing IVF: a novel
428 pretreatment counselling tool. *Human Reproduction*, 31(1), pp.84–92. Available at:
429 <http://humrep.oxfordjournals.org/lookup/doi/10.1093/humrep/dev268>.
- 430 Evans, K.N. et al., 2004. Vitamin D and placental-decidual function. *Journal of the Society for*
431 *Gynecologic Investigation*, 11(5), pp.263–271.
- 432 Fabris, A. et al., 2014. Impact of circulating levels of total and bioavailable serum vitamin D on
433 pregnancy rate in egg donation recipients. *Fertility and Sterility*, 102(6), pp.1608–1612.
- 434 Farzadi, L., Khayatzadeh Bidgoli, H. & Ghojzadeh, M., 2015. Correlation between follicular fluid 25-
435 OH vitamin D and assisted reproductive outcomes. *Iranian Journal of Reproductive Medicine*,
436 13(6), pp.361–366.
- 437 Firouzabadi, R.D. et al., 2014. Value of follicular fluid vitamin D in predicting the pregnancy rate in an
438 IVF program. *Archives of Gynecology and Obstetrics*, 289(1), pp.201–206.
- 439 Franasiak, J.M. et al., 2015. Vitamin D levels do not affect IVF outcomes following the transfer of
440 euploid blastocysts. *American Journal of Obstetrics and Gynecology*, 212(3), pp.315.e1–315.e6.
- 441 Garbedian, K. et al., 2013. Effect of vitamin D status on clinical pregnancy rates following in vitro
442 fertilization. *CMAJ Open*, 1(2), pp.E77–82. Available at:
443 <http://www.ncbi.nlm.nih.gov/pubmed/25077107>.
- 444 Gordon, C.M. et al., 2004. Prevalence of vitamin D deficiency among healthy adolescents. *Archives of*
445 *pediatrics & adolescent medicine*, 158(6), pp.531–537.
- 446 Grady, R. et al., 2012. Elective single embryo transfer and perinatal outcomes: A systematic review
447 and meta-analysis. *Fertility and Sterility*, 97(2), pp.324–331.
- 448 Halloran, B.P. & DeLuca, H.F., 1980. Effect of vitamin D deficiency on fertility and reproductive
449 capacity in the female rat. *J Nutr*, 110(8), pp.1573–1580.
- 450 Harbord, R.M., Egger, M. & Sterne, J., 2006. A modified test for small study effects in meta-analyses

- 451 of controlled trials with binary endpoints. *Stat. Med*, 25, pp.3443–3457.
- 452 Heaney, R.P., 2008. Vitamin D in health and disease. *Clinical journal of the American Society of*
453 *Nephrology : CJASN*, 3(5), pp.1535–41. Available at:
454 <http://www.ncbi.nlm.nih.gov/pubmed/18525006>.
- 455 Holick, M.F. et al., 2011. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine
456 Society clinical practice guideline. *The Journal of clinical endocrinology and metabolism*, 96(7),
457 pp.1911–30. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21646368>.
- 458 Holick, M.F., 2007. Vitamin D deficiency. *The New England journal of medicine*, 357(3), pp.266–281.
459 Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17634462>.
- 460 Human Fertility Embryology Authority, 2016. *Fertility Treatment 2014*,
- 461 Ingles, S.A., 2007. Can Diet and/or Sunlight Modify the Relationship between Vitamin D Receptor
462 Polymorphisms and Prostate Cancer Risk? *Nutrition Reviews*, 65(SUPPL.2).
- 463 John, E.M. et al., 2007. Sun exposure, vitamin D receptor gene polymorphisms, and breast cancer
464 risk in a multiethnic population. *American Journal of Epidemiology*, 166(12), pp.1409–1419.
- 465 Khalessi, N. et al., 2015. The Relationship between Maternal Vitamin D Deficiency and Low Birth
466 Weight Neonates. *Journal of family & reproductive health*, 9(3), pp.113–117. Available at:
467 [http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4662754&tool=pmcentrez&rende](http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4662754&tool=pmcentrez&render_type=abstract)
468 [rtpe=abstract\nhttp://www.ncbi.nlm.nih.gov/pubmed/26622309\nhttp://www.pubmedcentr](http://www.ncbi.nlm.nih.gov/pubmed/26622309)
469 [al.nih.gov/articlerender.fcgi?artid=PMC4662754](http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC4662754).
- 470 Kinuta, K. et al., 2000. Vitamin D is an important factor in estrogen biosynthesis of both female and
471 male gonads. *Endocrinology*, 141(4), pp.1317–1324.
- 472 Lerchbaum, E. & Rabe, T., 2014. Vitamin D and female fertility. *Current opinion in obstetrics &*
473 *gynecology*, 26(3), pp.145–50. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24717915>.
- 474 Liberati, A. et al., 2009. Annals of Internal Medicine Academia and Clinic The PRISMA Statement for
475 Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care
476 Interventions : *Annals of Internal Medicine*, 151(4), pp.W65–W94.

- 477 Macklon, N.S., Geraedts, J.P.M. & Fauser, B.C.J.M., 2002. Conception to ongoing pregnancy: The
478 “black box” of early pregnancy loss. *Human Reproduction Update*, 8(4), pp.333–343.
- 479 Moher, D. et al., 2009. Reprint--preferred reporting items for systematic reviews and meta-analyses:
480 the PRISMA statement. *Physical therapy*, 89(9), pp.873–880.
- 481 Moon, R.J., Harvey, N.C. & Cooper, C., 2015. ENDOCRINOLOGY IN PREGNANCY: Influence of maternal
482 vitamin D status on obstetric outcomes and the fetal skeleton. *European Journal of*
483 *Endocrinology*, 173(2), pp.R69–R83.
- 484 National Institute for Health and Care Excellence, N., 2013. Fertility: assessment and treatment for
485 people with fertility problems. *NICE CLinical Guidelines*, (May), p.274–. Available at:
486 [http://scholar.google.com/scholar?hl=en&btnG=Search&q=intitle:Fertility+:+assessment+and+](http://scholar.google.com/scholar?hl=en&btnG=Search&q=intitle:Fertility+:+assessment+and+treatment+for+people+with+fertility+problems#0\http://scholar.google.com/scholar?hl=en&btnG=Search&q=intitle:Fertility+:+assessment+and+treatment+for+people+with+fert.)
487 [treatment+for+people+with+fertility+problems#0\http://scholar.google.com/scholar?hl=en&](http://scholar.google.com/scholar?hl=en&btnG=Search&q=intitle:Fertility+:+assessment+and+treatment+for+people+with+fert.)
488 [btnG=Search&q=intitle:Fertility+:+assessment+and+treatment+for+people+with+fert.](http://scholar.google.com/scholar?hl=en&btnG=Search&q=intitle:Fertility+:+assessment+and+treatment+for+people+with+fert.)
- 489 Neville, G. et al., 2016. Vitamin D status and fertility outcomes during winter among couples
490 undergoing in vitro fertilization/intracytoplasmic sperm injection. *Int J Gynaecol Obstet.*,
491 135(2), pp.172–176.
- 492 Ozkan, S. et al., 2010. Replete vitamin D stores predict reproductive success following in vitro
493 fertilization. *Fertility and Sterility*, 94(4), pp.1314–1319.
- 494 Paffoni, A. et al., 2014. Vitamin D deficiency and infertility: Insights from in vitro fertilization cycles.
495 *Journal of Clinical Endocrinology and Metabolism*, 99(11), pp.E2372–E2376.
- 496 Panda, D.K. et al., 2001. Targeted ablation of the 25-hydroxyvitamin D 1alpha -hydroxylase enzyme:
497 evidence for skeletal, reproductive, and immune dysfunction. *Proceedings of the National*
498 *Academy of Sciences of the United States of America*, 98(13), pp.7498–7503.
- 499 Robinson, C.J. et al., 2011. Maternal vitamin D and fetal growth in early-onset severe preeclampsia.
500 *American Journal of Obstetrics and Gynecology*, 204(6).
- 501 Rojansky, N., Brzezinski, A. & Schenker, J.G., 1992. Seasonality in human reproduction: an update.
502 *Human Reproduction*, 7(6), pp.735–745.

- 503 Ross, A., Manson, J. & Abrams, S., 2011. The 2011 Report on Dietary Reference Intakes for Calcium
504 and Vitamin D from the Institute of Medicine: What Clinicians Need to Know. *The Journal of*
505 *Clinical Endocrinology and Metabolism*, 96(1), pp.53–58.
- 506 Rudick, B. et al., 2012. Characterizing the influence of vitamin D levels on IVF outcomes. *Human*
507 *Reproduction*, 27(11), pp.3321–3327.
- 508 Rudick, B. et al., 2010. Characterizing the role of vitamin D levels on IVF outcomes: stimulation,
509 embryo, or endometrium? *Fertility and Sterility*, 94(4), p.S72. Available at:
510 <http://linkinghub.elsevier.com/retrieve/pii/S0015028210013853>.
- 511 Rudick, B.J. et al., 2014. Influence of vitamin D levels on in vitro fertilization outcomes in donor-
512 recipient cycles. *Fertility and Sterility*, 101(2), pp.447–452.
- 513 Schünemann, H. et al., 2011. Cochrane Handbook for Systematic Reviews of Interventions Version
514 5.1.0. In *Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0*.
- 515 Stephanou, A., Ross, R. & Handwerger, S., 1994. Regulation of Human Placental Lactogen Expression
516 by 1,25-Dihydroxyvitamin D3. *Endocrinology*, 135(6), pp.2651–2656.
- 517 Sullivan, S.S. et al., 2005. Adolescent girls in maine are at risk for vitamin D insufficiency. *Journal of*
518 *the American Dietetic Association*, 105(6), pp.971–974.
- 519 Tangpricha, V. et al., 2002. Vitamin D insufficiency among free living healthy young adults. *American*
520 *Journal of Medicine*, 112(8), pp.659–662.
- 521 Wang, O. et al., 2012. Association between vitamin D insufficiency and the risk for gestational
522 diabetes mellitus in pregnant Chinese women. *Biomedical and environmental sciences : BES*,
523 25(4), pp.399–406. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23026519>.
- 524 Wei, S.Q., 2014. Vitamin D and pregnancy outcomes. *Current opinion in obstetrics & gynecology*,
525 26(6), pp.438–47. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25310531>.
- 526 Wells, G. et al., 2011. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised
527 studies in meta-analysis. 2011. , p.http://www.ohri.ca/programs/clinical_epidemiolog.
- 528 Yoshizawa, T. et al., 1997. Mice lacking the vitamin D receptor exhibit impaired bone formation,

529 uterine hypoplasia and growth retardation after weaning. *Nature genetics*, 16(4), pp.391–396.
530 Available at:
531 <http://www.ncbi.nlm.nih.gov/pubmed/9241280>\n[http://www.nature.com/ng/journal/v16/n4/](http://www.nature.com/ng/journal/v16/n4/abs/ng0897-391.html)
532 [abs/ng0897-391.html](http://www.nature.com/ng/journal/v16/n4/abs/ng0897-391.html).

533 Zhang, M.X. et al., 2015. Vitamin D deficiency increases the risk of gestational diabetes mellitus: A
534 meta-analysis of observational studies. *Nutrients*, 7(10), pp.8366–8375. Available at:
535 [http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed13&AN=2](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed13&AN=2015431828)
536 [015431828](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed13&AN=2015431828)\n[http://sfx.ucl.ac.uk/sfx_local?sid=OVID:embase&id=pmid:&id=doi:10.3390/nu710](http://sfx.ucl.ac.uk/sfx_local?sid=OVID:embase&id=pmid:&id=doi:10.3390/nu7105398&issn=2072-6643&isbn=&volume=7&issue=10&spage=8366&pages=8366-8375&date=2015&title)
537 [539 \[541 \\[8375&date=2015&title\\]\\(http://sfx.ucl.ac.uk/sfx_local?sid=OVID:embase&id=pmid:&id=doi:10.3390/nu7105398&issn=2072-6643&isbn=&volume=7&issue=10&spage=8366&pages=8366-8375&date=2015&title\\).\]\(http://sfx.ucl.ac.uk/sfx_local?sid=OVID:embase&id=pmid:&id=doi:10.3390/nu7105398&issn=2072-6643&isbn=&volume=7&issue=10&spage=8366&pages=8366-
540 <a href=\)](http://sfx.ucl.ac.uk/sfx_local?sid=OVID:embase&id=pmid:&id=doi:10.3390/nu7105398&issn=2072-6643&isbn=&volume=7&issue=10&spage=8366&pages=8366-
538 <a href=)

542 **Figure Legends**

543 Figure 1. PRISMA flow diagram for study selection.

544

545 Figure 2. Meta-analysis of studies reporting live birth by vitamin D concentrations. Meta-analysis of
546 the data from seven included studies that reported live birth as an outcome showed that women
547 who are vitamin D replete have a higher chance of achieving a live birth from ART when compared
548 with women with vitamin D deficiency or insufficiency. F-H, Fixed; Fixed effects (Mantel-Haenszel)

549

550 Figure 3. Meta-analysis of studies reporting biochemical pregnancy by vitamin D concentrations.

551 Meta-analysis of the data from five included studies that reported biochemical pregnancy as an
552 outcome showed that women who are vitamin D replete have a higher chance of achieving a
553 positive pregnancy test from ART when compared with women with vitamin D deficiency or
554 insufficiency.

555

556 Figure 4. Meta-analysis of studies reporting clinical pregnancy by vitamin D concentrations. Meta-
557 analysis of the data from all 11 of the included studies that reported clinical pregnancy as an
558 outcome showed that women who are vitamin D replete have a higher chance of achieving clinical
559 pregnancy from ART when compared with women with vitamin D deficiency or insufficiency.

560

561 Figure 5. Meta-analysis of studies reporting clinical pregnancy by vitamin D concentrations according
562 to source of oocyte. Meta-analysis of the data from nine included studies showed that women who
563 are vitamin D replete have a higher chance of achieving a clinical pregnancy from ART using
564 autologous oocytes when compared with women with vitamin D deficiency or insufficiency. Meta-
565 analysis of the data from two included studies showed no difference in the chance of clinical
566 pregnancy in women replete, insufficient or deficient in vitamin D undergoing ART using donor
567 oocytes.

568

569 Figure 6. Meta-analysis of studies reporting miscarriage by vitamin D concentrations. Meta-analysis
570 of the data from six included studies that reported miscarriage as an outcome showed no difference
571 in the chance of miscarriage in women replete, insufficient or deficient in vitamin D undergoing ART.

572

573 Supplementary Figure S1. Vitamin D and *in vitro* fertilisation treatment clinical pregnancy outcomes
574 publication bias funnel plot. The funnel plot to test for asymmetry showed no substantial evidence
575 of publication bias.

576

577 Supplementary Figure S2. Meta-analysis of studies reporting clinical pregnancy by vitamin D
578 concentrations implementing Institute of Medicine cut-offs. Data could be extracted from nine of
579 the included studies to compare the chances of clinical pregnancy by using the Institute of Medicine
580 definitions of vitamin D status (vitamin D concentrations of less than 50nmol/L considered as
581 deficient or insufficient and vitamin D concentrations of more than 50nmol/L considered replete).
582 Meta-analysis of the data from these nine studies showed that women who are vitamin D replete
583 have a higher chance of achieving clinical pregnancy from ART when compared with women with
584 vitamin D deficiency or insufficiency according to Institute of Medicine vitamin D cut-offs.

1 Vitamin D and assisted reproductive treatment outcome: A systematic review and meta-analysis

2

3 **RUNNING TITLE**

4 Vitamin D and assisted reproductive treatment outcome

5

6 **AUTHORS**

7 Justin Chu^{1,2}, Ioannis Gallos^{1,2*}, Aurelio Tobias^{1,3}, Bee Tan^{4,5}, Abey Eapen^{1,2} and Arri Coomarasamy^{1,2}

8

9

10 ¹Tommy's National Centre for Miscarriage Research, Institute of Metabolism and Systems Research,
11 University of Birmingham, Birmingham, B15 2TT, UK

12 ²Birmingham Women's and Children's NHS Foundation Trust, Mindelsohn Way, Birmingham, B15
13 2TG, UK

14 ³Spanish Council for Scientific Research, Institute of Environmental Assessment and Water Research,
15 Barcelona, Spain

16 ⁴Heartlands Hospital, Heart of England NHS Foundation Trust, Bordesley Green East, Birmingham B9
17 5SS, UK

18 ⁵Reproductive health, Warwick University, Coventry, CV4 7AL, UK

19

20 ***CORRESPONDENCE ADDRESS:** Email i.d.gallos@bham.ac.uk, Birmingham Women's Foundation

21 NHS Trust, Edgbaston, B15 2TG

22

23

24 **ABSTRACT**

25

26 **Study question:** Is serum vitamin D associated with live birth rates in women undergoing assisted
27 reproductive treatment?

28

29 **Summary answer:** Women undergoing assisted reproductive treatment who are replete in vitamin D
30 have a higher live birth rate than women who are vitamin D deficient or insufficient.

31

32 **What is known already:** Vitamin D deficiency has been associated with an increased risk of
33 abnormal pregnancy implantation as well as obstetric complications such as pre-eclampsia and fetal
34 growth restriction. However, the effect of vitamin D on conception and early pregnancy outcomes in
35 couples undergoing assisted reproductive treatment is poorly understood.

36

37 **Study design, size, duration:** A systematic review and meta-analysis of 11 published cohort studies
38 (including 2700 women) investigating the association between vitamin D and assisted reproductive
39 treatment outcomes.

40

41 **Participants/materials, settings, methods:** Literature searches were conducted to retrieve studies
42 which reported on the association between vitamin D and assisted reproductive treatment
43 outcomes. Databases searched included MEDLINE, EMBASE, Cochrane Central Register of Controlled
44 Trials and CINAHL. Eleven studies matched the inclusion criteria.

45

46 **Main results and the role of chance:** Live birth was reported in seven of the included studies
47 (including 2026 patients). Live birth was found to be more likely in women replete in vitamin D when
48 compared to women with deficient or insufficient vitamin D status (OR 1.33 [1.08 to 1.65]). Five
49 studies (including 1700 patients) found that women replete in vitamin D were more likely to achieve

50 a positive pregnancy test than women deficient or insufficient in vitamin D (OR 1.34 ([1.04 to 1.73]).
51 All 11 of the included studies (including 2700 patients) reported clinical pregnancy as an outcome.
52 Clinical pregnancy was found to be more likely in women replete in vitamin D (OR 1.46[1.05 to
53 2.02]). Six studies (including 1635 patients) reported miscarriage by vitamin D concentrations. There
54 was no association found between miscarriage and vitamin D concentrations (OR 1.12 [0.81 to 1.54]).
55 The included studies scored well on the Newcastle Ottawa quality assessment scale.

56

57 **Limitations, reasons for caution:** Although strict inclusion criteria were used in the conduct of the
58 systematic review, the included studies are heterogeneous in population characteristics and fertility
59 treatment protocols.

60

61 **Wider implications of the findings:** The findings of this systematic review show that there is an
62 association between vitamin D status and reproductive treatment outcomes achieved in women
63 undergoing assisted reproductive treatment. Our results show that vitamin D deficiency and
64 insufficiency could be important conditions to treat in women considering assisted reproductive
65 treatments. A randomised controlled trial to investigate the benefits of vitamin D deficiency
66 treatment should be considered to test this hypothesis.

67

68 **Study funding/competing interests:** No external funding was either sought or obtained for this
69 study. The authors have no competing interests to declare.

70

71 **Registration number:** N/A

72

73 **Key words:** Vitamin D / Implantation / Assisted reproductive treatments / In vitro fertilisation /
74 Endometrial receptivity

75

76 **INTRODUCTION**

77 Infertility causes great psychological and sometimes physical distress to one in seven couples
78 (National Institute for Health and Care Excellence 2013). In the United Kingdom (UK), in 2014, 52,288
79 women underwent 67,708 in vitro fertilization (IVF) treatment cycles (Human Fertility Embryology
80 Authority 2016). The overall success rate of these assisted reproductive treatments (ART) was 36.3%
81 (Human Fertility Embryology Authority 2016). Since the availability of ART treatment has become
82 more widespread, success rates have gradually increased (Grady et al. 2012). This has largely been
83 due to the research conducted in embryology, which has enhanced our abilities to select and
84 transfer the embryo with the highest pregnancy potential. More recently, the rate of improvement
85 in success rates has slowed (Busso et al. 2006). There remains ample room for improvement in
86 fertility treatments to maximize the chances of achieving pregnancy. Much of this lies in improving
87 the likelihood for implantation of the selected embryo that is transferred in to the uterus (Macklon
88 et al. 2002).

89

90 There has been recent interest in the role of vitamin D in reproductive physiology as findings have
91 shown that as much as 20 to 52% of women of reproductive age are deficient in vitamin D (Gordon
92 et al. 2004; Sullivan et al. 2005; Tangpricha et al. 2002). It is postulated that vitamin D is important in
93 the process of pregnancy implantation as vitamin D enzymes and receptors have been found in the
94 endometrium (Lerchbaum & Rabe 2014). Additionally, vitamin D deficiency has been found to cause
95 decreased fertility capacity, hypogonadism and uterine hypoplasia in animal studies (Halloran &
96 DeLuca 1980; Kinuta et al. 2000; Yoshizawa et al. 1997; Panda et al. 2001). In humans, the
97 importance of vitamin D in placental function is the most studied aspect of vitamin D in reproduction
98 (Aghajafari et al. 2013). Specifically, vitamin D deficiency has been linked to poor placentation,
99 leading to hypertensive disorders of pregnancy (pre-eclampsia and pregnancy induced hypertension)
100 and fetal growth restriction (Aghajafari et al. 2013). More recently, it has been proposed that
101 vitamin D may be a regulator of initial embryo implantation and that improper implantation, due to

102 vitamin D deficiency, is the cause of poor placentation (Bodnar et al. 2007; Baker et al. 2010;
103 Robinson et al. 2011).

104

105 Our main source of vitamin D, a fat-soluble steroid hormone, is from sunlight. Only a small amount is
106 obtained from our diet. The majority of the body's vitamin D is in the form of vitamin D₃
107 (cholecalciferol), which is photo-chemically synthesized in the skin (Holick 2007).

108

109 Vitamin D concentrations are usually measured by assay of serum 25-hydroxy vitamin D₃ status.

110 Experts in nutrition have suggested that people are at risk of the detrimental effects of vitamin D

111 deficiency at serum 25-hydroxy vitamin D₃ concentrations of less than 50 nmol/L (less than

112 20ng/mL). A concentration of 50 to 75 nmol/L (21 to 29 ng/mL) is considered insufficient and greater

113 than 75nmol/L (greater than 30 ng/ml) is considered vitamin D replete. These vitamin D

114 concentration cut-offs are those adopted by the Endocrine Society (Holick et al. 2011). Differing

115 vitamin D concentration cut-offs have also been proposed by the Institute of Medicine (IOM), who

116 suggest that vitamin D deficiency is when serum 25-hydroxy vitamin D₃ concentrations are less than

117 30 nmol/L (less than 12ng/mL), vitamin D insufficiency is when serum 25-hydroxy vitamin D₃

118 concentrations are between 30 nmol/L and 50nmol/L (between 12 and 20ng/mL), and that serum

119 25-hydroxy vitamin D₃ concentrations greater than 50nmol/L (greater than 20ng/mL) are considered

120 replete (Ross et al. 2011). There is agreement that serum concentrations greater than 374 nmol/L

121 (greater than 150 ng/mL) are associated with toxicity and adverse effects (Tangpricha et al. 2002;

122 Heaney 2008; Stephanou et al. 1994; Daftary & Taylor 2006).

123

124 The biological plausibility that vitamin D plays an important role in implantation has led research

125 groups to investigate the importance of vitamin D in patients undergoing ART. Some studies have

126 found that replete concentrations of vitamin D lead to an increase in clinical pregnancy and live birth

127 rates (Rudick et al. 2014; Ozkan et al. 2010; Rudick et al. 2012; Garbedian et al. 2013; Paffoni et al.

128 2014). However, others have found conflicting evidence suggesting that vitamin D has no effect on
129 the outcome of ART (Anifandis et al. 2010; Aleyasin et al. 2011; Firouzabadi et al. 2014; Fabris et al.
130 2014; Franasiak et al. 2015). The aim of our review was to investigate the association between
131 vitamin D status and reproductive outcomes by meta-analysis of the ART outcomes of published
132 cohort studies to summarise the available evidence.

133 **METHODS**

134 **Inclusion Criteria**

135 The study was designed a priori with inclusion of primary articles that studied women undergoing
136 any form of ART (IVF, ICSI and frozen embryo transfer [FET]) who had their vitamin D status checked.
137 This could either be through blood serum or follicular fluid assay. The primary outcome was live
138 birth rates according to vitamin D status. Secondary outcomes included biochemical pregnancy
139 rates, and clinical pregnancy rates.

140

141 **Literature search**

142 MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials and CINAHL (from inception to
143 April 2017) were searched. The search strategy used the following key words and/or medical subject
144 heading (MeSH) terms: pregnancy, *in vitro* fertilization, intracytoplasmic sperm injection, assisted
145 reproductive techniques and vitamin D. The full electronic search strategy is provided in
146 Supplementary Table SI. References of all included primary and review articles were examined to
147 identify relevant articles not captured by the electronic searches. No language restrictions were
148 applied in any of the searches or study selection.

149

150 **Study selection**

151 Criteria for inclusion in the study were established prior to the literature search. Two independent
152 reviewers (J.C. and B.T.) carried out study selection. First, the independent reviewers scrutinized the
153 titles and abstracts of the electronic searches. Each title and abstract were included or excluded
154 independently according to the predefined inclusion criteria; any disagreements regarding inclusion
155 were resolved by a further reviewer (I.D.G). The full manuscripts of the titles and abstracts
156 considered to be relevant for inclusion were obtained. When there was a duplicate publication, the
157 most recent and complete version was selected and included. Studies that did not explicitly report
158 results from assisted reproductive treatments according to vitamin D groups (deficient, insufficient
159 and replete) according to Endocrine Society guidelines were excluded.

160

161 The same two independent reviewers (J.C. and B.T.) extracted the outcome data from the included
162 studies.

163

164 **Study quality assessment**

165 Two reviewers (J.C and B.T.) used the Newcastle-Ottawa Quality Assessment Scales for observational
166 studies to complete a quality assessment of the included manuscripts(Wells et al. 2011). The
167 Newcastle-Ottawa scale ranges from zero to nine, awarding one star for all categories (case-cohort
168 representative, ascertainment of exposure, outcome negative at commencement of study, outcome
169 assessment, duration of follow up and adequacy of follow up) except comparability by design or
170 analysis where two stars can be awarded. An arbitrary score was allocated assuming that all items
171 have equal weighting. This was used to give a quantitative appraisal of overall quality of the
172 individual studies. Each study received a score from each of the reviewers.

173

174 Publication Bias

175 Assessment for publication bias in the included studies for the outcome of clinical pregnancy was
176 performed using Harbord's modified test for small study effects to assess for funnel plot asymmetry
177 ((Harbord et al. 2006).

178 Statistical analysis

179 Live birth, biochemical pregnancy, clinical pregnancy and miscarriage rates were extracted from
180 each of the included studies according to vitamin D strata. The log of the ratio and its corresponding
181 standard error for each study was computed. Meta-analysis using inverse-variance weighting was
182 performed to calculate the random-effects summary estimates. The square root of this number is
183 the estimated standard deviation of the underlying effects across studies. Because we had relative
184 measures of effect, the confidence intervals were centered on the natural logarithm of the pooled
185 estimate and the limits exponentiated to obtain an interval on the ratio scale. Forest plots were
186 created for each outcome, showing individual study proportions with confidence intervals (CIs) and
187 the overall DerSimonian-Laird pooled estimate according to vitamin D status. Heterogeneity of the
188 treatment effects was assessed graphically with forest plots and statistically analyzed using the χ^2
189 test. Statistical analyses were performed using Stata 12.1 (StataCorp, College Station, TX).

190 RESULTS

191 The PRISMA flow diagram (Liberati et al. 2009; Moher et al. 2009) of the review process is presented
192 in Fig. 1. The search strategy yielded 4615 citations, of which 4505 citations were excluded as it was
193 clear from scrutinizing the title and abstract that they did not fulfil the selection criteria. Full
194 manuscripts of 110 articles were obtained. A total of 99 of these publications were excluded because
195 35 were reviews, 24 articles did not specify outcomes from ART, 17 articles did not specify
196 investigating vitamin D, seven articles were conference abstracts or studies where there was no
197 extractable data (Farzadi et al. 2015; Neville et al. 2016) (as they provided mean vitamin D
198 concentrations of groups of women achieving clinical pregnancy and those that did not) , five articles

199 reported male infertility, four articles were animal studies, three were letters, two were duplicates,
200 and one was a study protocol. Therefore, the total number of observational studies included in the
201 review was 11.

202

203 **Study characteristics**

204 Study characteristics of the 11 included studies are presented in Table I. None of the included
205 studies declared any conflicts of interest. The included studies varied in publication date between
206 2010 and 2015. All 11 included studies were cohort studies; six were retrospective and five were
207 prospective in design. Sample sizes varied between 84 women to 517 women. Nine of the 11
208 included studies reported the ages of their study population. Seven studies had a mean age of below
209 37 years and two had a higher mean age of 40.5 and 40.9 years. Eight included studies used serum
210 measurement of vitamin D, two used both follicular fluid and serum vitamin D (finding that there
211 was high correlation between the follicular fluid vitamin D and serum vitamin D in their participants),
212 and one study used follicular fluid alone. Of the 11 included studies, nine studies reported ART
213 where women had used autologous oocytes. Two reported results from women who were donor
214 egg recipients. One study used pre-implantation genetic screening to ensure that patients had
215 karyotypically normal embryos transferred. One study chose to only study women that underwent a
216 single blastocyst transfer. All of the 11 included studies assayed 25-hydroxy-vitamin D. Four of the
217 included studies assessed vitamin D before the commencement of the treatment cycle, three
218 assessed vitamin D at the time of ovulation trigger, three assessed vitamin D at the time of oocyte
219 retrieval, and one study assessed vitamin D just before oocyte retrieval. All of the 11 included
220 studies used the Endocrine Society classification of vitamin D status (less than 50nmol/L deficient,
221 50-75nmol/L insufficient, and greater than 75nmol/L replete). Six of the included studies provided
222 adjusted odds ratios, adjusting for potential confounding factors. Of these six studies, only four
223 provided adequate detail for potential meta-analysis of adjusted odds ratios. However, two of these

224 studies had adjusted for vitamin D concentration and another two studies had used differing
225 referent groups to obtain adjusted odds ratios.

226

227 A funnel plot to test for asymmetry did not find substantial evidence of publication bias ($p=0.933$)
228 (Supplementary Figure S1).

229

230 All studies scored well using the Newcastle-Ottawa Quality Assessment achieving a score between 7
231 and 9 (Table II).

232

233

234 **Vitamin D deficiency prevalence**

235 Our review found a high prevalence of vitamin D deficiency. The meta-analysed prevalence for
236 vitamin D deficiency, insufficiency and replete were 34.6% (95% CI 32.0 to 37.4), 45.3% (95% CI 42.4
237 to 48.5) and 25.7% (95% CI 23.4 to 28.2%) respectively.

238

239 **Live birth**

240 Seven studies (2026 participants) reported the live births achieved by women when categorized by
241 vitamin D (Fig. 2). Meta-analysis of the data from these studies showed that women who are vitamin
242 D replete have a higher chance of achieving a live birth from ART when compared with women with
243 vitamin D deficiency or insufficiency. The odds ratio was 1.33 (1.08 to 1.65). The meta-analysis had
244 low statistical heterogeneity with an I^2 value of 5.0% ($p=0.39$).

245

246 **Biochemical pregnancy**

247 Five studies (1700 participants) reported the number of women that achieved a positive pregnancy
248 test approximately two weeks after embryo transfer for the three vitamin D categories. The odds of

249 biochemical pregnancy in the vitamin D deficient and insufficient population versus the vitamin D
250 replete population are presented in Fig. 3. Meta-analysis of these five cohort studies showed a
251 greater chance of pregnancy in the vitamin D replete group when compared with the vitamin D
252 deficient and insufficient groups with an odds ratio of 1.34 (1.04 to 1.73). There was a low level of
253 statistical heterogeneity with an I^2 value of 21.0% ($p=0.28$).

254

255 **Clinical pregnancy**

256 All 11 studies (2700 participants) reported on clinical pregnancy rate (the presence of fetal heart
257 approximately five weeks after embryo transfer) as an outcome (Fig. 4). Pooling of the clinical
258 pregnancy outcomes from the 11 studies showed an improved chance of clinical pregnancy in the
259 vitamin D replete population when compared with the vitamin D deficient and insufficient
260 population. The vitamin D replete group was more likely to achieve clinical pregnancy when
261 compared with the vitamin D deficient and insufficient groups with an odds ratio of 1.46 (1.05 to
262 2.02). The I^2 value for this meta-analysis was 61.0% suggesting a moderate level of statistical
263 heterogeneity ($p=0.02$).

264

265 Data could be extracted from nine of the included studies (2082 patients) to compare the chances of
266 clinical pregnancy by using the IOM definitions of vitamin D status (vitamin D concentrations of less
267 than 50nmol/L considered as deficient or insufficient and vitamin D concentrations of more than
268 50nmol/L considered replete). Pooling of the clinical pregnancy rates from these nine studies also
269 showed that women with a vitamin D concentration of greater than 50nmol/L were more likely to
270 achieve a clinical pregnancy when compared to women with a vitamin D concentration of below
271 50nmol/L with an odds ratio of 1.38 (1.04 to 1.83) (Supplementary Figure S2).

272

273 Clinical pregnancy according to source of oocyte used

274 The 11 included studies were divided into two groups according to the source of the oocyte
275 (autologous or donor) used to form the embryo for transfer (Fig. 5). Nine studies (including 2334
276 patients) reported fertility outcomes in infertile women receiving an autologous oocyte embryo.
277 Clinical pregnancy was found to be more likely in women who were vitamin D replete who received
278 an autologous oocyte embryo (OR 1.39 [1.00 to 1.93]). The I^2 value for this meta-analysis was 56.0%
279 suggesting a moderate level of statistical heterogeneity ($p=0.02$).

280

281 In the two studies (including 366 patients) where women received a donor oocyte embryo, no
282 significant difference was found when comparing the clinical pregnancy in women receiving a donor
283 oocyte embryo who were vitamin D replete when compared to women who were vitamin D
284 deficient or insufficient (OR 2.02 [0.44 to 9.26]). The I^2 value for this meta-analysis was 85.0%
285 suggesting a considerable level of statistical heterogeneity ($p=0.009$).

286

287 Miscarriage

288 Six studies (1635 participants) reported on the outcome of miscarriage (Fig. 6). When the data from
289 these six studies are pooled, the chance of miscarriage in the vitamin D replete women is similar to
290 that of vitamin D deficient and insufficient women with an odds ratio of 1.12 (0.81 to 1.54). There
291 was a low level of statistical heterogeneity denoted by an I^2 value of 0.0% ($p=0.76$).

292

293 DISCUSSION

294 This systematic review including 11 studies suggests that the chances of achieving a live birth, a
295 positive pregnancy test and clinical pregnancy after ART are higher in women who are vitamin D
296 replete when compared to those who are vitamin D deficient or insufficient. Miscarriage does not
297 appear to be associated with vitamin D status.

298

299 Our analysis was strengthened by a number of factors. A comprehensive search strategy was used,
300 employing relevant research databases. Additionally, a valid data synthesis method was
301 implemented and no language restrictions were applied. The Newcastle-Ottawa Quality Assessment
302 Scale was used to assess the quality of the included studies. The assessment of all studies scored
303 well on this scale, suggesting low risk of bias.

304

305 There are also weaknesses in our analysis, which mainly stem from the clinical heterogeneity of the
306 publications that were included. Some degree of heterogeneity is to be expected due to the
307 different geographical locations that the individual cohort studies have been conducted, leading to
308 differing population characteristics and ART protocols used. However, this is not necessarily a
309 disadvantage as some degree of clinical heterogeneity can increase the generalisability of the
310 findings to wider infertility populations.

311

312 Ideally, when meta-analysing cohort studies, the adjusted odds ratios (where provided) should be
313 meta-analysed. However, in our included studies it was infrequent for the included primary studies
314 to have provided sufficient detail of their adjusted analysis for known confounding factors such as
315 age and BMI. Therefore, we were unable to perform a meta-analysis of adjusted odds ratios.

316

317 One source of clinical heterogeneity between the included studies is in the timing of vitamin D
318 assessment. Some of the studies measured their participants' vitamin D status before the start of
319 ART, whereas others measured vitamin D at the time of oocyte retrieval. Vitamin D status is known
320 to not fluctuate over time unless vitamin D deficiency or insufficiency is actually treated (Anagnostis
321 et al. 2013). Therefore, the importance of the difference in timing of the vitamin D assessment
322 reduces.

323

324 There were also differences in the bio-fluid used to assess vitamin D status amongst the included
325 studies. Three of the included studies measured vitamin D in the follicular fluid aspirated at the time
326 of oocyte retrieval. The remaining studies used blood serum for vitamin D measurement.
327 Reassuringly, a number of previously published studies have found that assays of vitamin D in
328 follicular fluid or blood serum produce results that are highly correlative (Aleyasin et al. 2011;
329 Anifandis et al. 2010; Firouzabadi et al. 2014; Ozkan et al. 2010). Serum vitamin D would be
330 measured more conveniently in women undergoing ART and could be tested before the start of
331 treatment to allow time for correction of deficiency.

332

333 We found that the likelihood of achieving a positive pregnancy test after embryo transfer was higher
334 in women who were replete in vitamin D. This would support the hypothesis that vitamin D affects
335 embryo implantation. Two of the included studies have tried to investigate the effect of vitamin D on
336 implantation further by only including women undergoing oocyte recipient treatment cycles (Fabris
337 et al. 2014; Rudick et al. 2014). Isolating recipients of donor oocyte embryos aims to reduce the
338 impact of oocyte quality on reproductive outcomes. Donated oocytes would be sourced from
339 younger women with higher quality oocytes and therefore implantation can be investigated more
340 accurately. Meta-analysis of the clinical pregnancy data from these two studies (including 366
341 patients) did not show a statistically significant difference in chance of clinical pregnancy between
342 the vitamin D replete and vitamin D deficient or insufficient populations. However, the data

343 ~~may does suggest show a trend towards~~ a higher chance of clinical pregnancy in the vitamin D
344 replete group. It is likely that the failure to reach statistical significance is due to the low number of
345 participants in view of the wide confidence intervals (Schünemann et al. 2011). Removal of these
346 two studies from the overall analysis did not alter the overall association between vitamin D
347 concentration and clinical pregnancy.

348

Comment [JC1]: I have just deleted 3 words here. Deleting the whole sentence would lose the message that is being conveyed.

Comment [RC2]: The use of the term trend is misleading as trend analysis was not performed and interpretation may be bias to an expected outcome. I would recommend deleting the sentence.

349 Seasonal variations in conception rates have been established (Rojansky et al. 1992) with higher
350 conception rates found in the Summer and Autumn. Although many hypotheses have been
351 postulated to explain this phenomenon (e.g. reduced ovulation rates and poorer sperm quality in
352 darker months) the exact mechanism behind this has not been explained. It is possible that an
353 increase in sun exposure and greater sunlight luminosity increases the body's store of vitamin D,
354 thereby yielding higher conception rates in Summer and Autumn.

355

356 Although the debate regarding the importance of vitamin D and seasonal variation in reproductive
357 health continues, its impact on immunomodulation within the endometrium with a resultant
358 reduction in active inflammatory cytokines is now well understood (Holick 2007). The expression of
359 vitamin D receptors at the level of the endometrium and the role of vitamin D in the transcription of
360 HOX10A gene (found to be of key importance in implantation) suggest that the immunomodulatory
361 effects of vitamin D may have a direct impact on implantation and therefore the likelihood of
362 reproductive treatment success (Evans et al. 2004).

363

364 Ethnicity has also been found to be a prognostic marker for IVF treatment success, with women of
365 Asian and Black ethnic origins having worse reproductive outcomes (Dhillon et al. 2016). One
366 possible explanation for this finding could be lower serum vitamin D concentrations in these ethnic
367 groups or differences in the vitamin D receptor gene polymorphisms (Ingles 2007; John et al. 2007).

368

369 Our review demonstrates that replete vitamin D status is associated with greater chances of ART
370 success. This could be via the actions of vitamin D on the endometrium promoting embryo

371 implantation or as a surrogate marker for general well-being (Lerchbaum & Rabe 2014). Vitamin D
372 serum testing is relatively cheap and widely available and its treatment is not costly. Therefore it
373 may be beneficial to diagnose and treat vitamin D deficiency in women planning ART to optimize
374 their pregnancy outcomes. Correction of vitamin D deficiency in these patients would also be of

Comment [RC3]: Such as a diet deficiency in general? If so would it be beneficial to diagnose for other micro-nutrient deficiencies?

Comment [JC4]: Vitamin D has been suggested to be a surrogate marker for general well-being. I have added the reference here. The same reference has been used previously in the manuscript so there is no need to change the reference list.

375 benefit during pregnancy, as replete vitamin D concentrations have been found to reduce the risk of
376 obstetric complications such as gestational diabetes (Wang et al. 2012; Zhang et al. 2015), pre-
377 eclampsia (Moon et al. 2015; De-Regil et al. 2012; Wei 2014), and fetal growth restriction (Conde-
378 Agudelo et al. 2013; Khalessi et al. 2015). To further investigate the value of treatment of vitamin D
379 deficiency in the infertile population an interventional trial would be necessary.

380 **Acknowledgments**

381 The authors would like to acknowledge Derick Yates (Birmingham Women's and Children's NHS
382 Foundation Trust) who helped design the search strategy for the systematic review and meta-
383 analysis.

384

385 **Authors' roles**

386 JC and AC were responsible for defining the research question. JC designed the strategy for literature
387 search. JC and BT assessed eligibility of studies for inclusion to the systematic review. Statistical
388 analyses were performed by AT and IDG. [AE assisted in the design of the systematic review search
389 strategy and in manuscript preparation.](#) JC wrote the first draft of the manuscript and is its
390 guarantor. All authors revised it critically for important intellectual content and gave final approval
391 of the version to be published.

392

393 **Funding**

394 No external funding was either sought or obtained for this study.

395

396 **Conflicts of interest**

397 None to declare

398

Comment [RC5]: Please include the details of the contributions from all authors; AE is missing.

Comment [JC6]: AE author contribution added

399 **References**

- 400 Aghajafari, F. et al., 2013. Association between maternal serum 25-hydroxyvitamin D level and
401 pregnancy and neonatal outcomes: systematic review and meta-analysis of observational
402 studies. *BMJ*, 346, p.f1169. Available at:
403 <http://www.ncbi.nlm.nih.gov/pubmed/23533188>
404 <http://www.bmj.com/content/bmj/346/bmj.f1169.full.pdf>.
- 405 Aleyasin, A. et al., 2011. Predictive value of the level of vitamin D in follicular fluid on the outcome of
406 assisted reproductive technology. *Eur J Obstet Gynecol Reprod Biol*, 159(1), pp.132–137.
- 407 Anagnostis, P., Karras, S. & Goulis, D.G., 2013. Vitamin D in human reproduction: A narrative review.
408 *International Journal of Clinical Practice*, 67(3), pp.225–235.
- 409 Anifandis, G.M. et al., 2010. Prognostic value of follicular fluid 25-OH vitamin D and glucose levels in
410 the IVF outcome. *Reproductive biology and endocrinology : RB&E*, 8, p.91.
- 411 Baker, A.M. et al., 2010. A Nested Case-Control Study of Midgestation Vitamin D Deficiency and Risk
412 of Severe Preeclampsia. *The Journal of Clinical Endocrinology & Metabolism*, 95(11), pp.5105–
413 5109. Available at: <http://press.endocrine.org/doi/abs/10.1210/jc.2010-0996>.
- 414 Bodnar, L.M. et al., 2007. Maternal vitamin D deficiency increases the risk of preeclampsia. *The*
415 *Journal of clinical endocrinology and metabolism*, 92(9), pp.3517–22. Available at:
416 <http://press.endocrine.org/doi/full/10.1210/jc.2007-0718>.
- 417 Busso, C.E. et al., 2006. Implantation in IVF. *International Surgery*, 91(5 SUPPL.).
- 418 Conde-Agudelo, A. et al., 2013. Novel biomarkers for predicting intrauterine growth restriction: A
419 systematic review and meta-analysis. *BJOG: An International Journal of Obstetrics and*
420 *Gynaecology*, 120(6), pp.681–694.
- 421 Daftary, G.S. & Taylor, H.S., 2006. Endocrine regulation of HOX genes. *Endocrine Reviews*, 27(4),
422 pp.331–355.
- 423 De-Regil, L.M. et al., 2012. Vitamin D supplementation for women during pregnancy. *Cochrane*
424 *database of systematic reviews (Online)*, 2(2), p.CD008873. Available at:

- 425 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008873.pub2/pdf/standard\http://>
426 www.ncbi.nlm.nih.gov/pubmed/22336854.
- 427 Dhillon, R.K. et al., 2016. Predicting the chance of live birth for women undergoing IVF: a novel
428 pretreatment counselling tool. *Human Reproduction*, 31(1), pp.84–92. Available at:
429 <http://humrep.oxfordjournals.org/lookup/doi/10.1093/humrep/dev268>.
- 430 Evans, K.N. et al., 2004. Vitamin D and placental-decidual function. *Journal of the Society for*
431 *Gynecologic Investigation*, 11(5), pp.263–271.
- 432 Fabris, A. et al., 2014. Impact of circulating levels of total and bioavailable serum vitamin D on
433 pregnancy rate in egg donation recipients. *Fertility and Sterility*, 102(6), pp.1608–1612.
- 434 Farzadi, L., Khayatzaideh Bidgoli, H. & Ghojzadeh, M., 2015. Correlation between follicular fluid 25-
435 OH vitamin D and assisted reproductive outcomes. *Iranian Journal of Reproductive Medicine*,
436 13(6), pp.361–366.
- 437 Firouzabadi, R.D. et al., 2014. Value of follicular fluid vitamin D in predicting the pregnancy rate in an
438 IVF program. *Archives of Gynecology and Obstetrics*, 289(1), pp.201–206.
- 439 Franasiak, J.M. et al., 2015. Vitamin D levels do not affect IVF outcomes following the transfer of
440 euploid blastocysts. *American Journal of Obstetrics and Gynecology*, 212(3), pp.315.e1–315.e6.
- 441 Garbedian, K. et al., 2013. Effect of vitamin D status on clinical pregnancy rates following in vitro
442 fertilization. *CMAJ Open*, 1(2), pp.E77–82. Available at:
443 <http://www.ncbi.nlm.nih.gov/pubmed/25077107>.
- 444 Gordon, C.M. et al., 2004. Prevalence of vitamin D deficiency among healthy adolescents. *Archives of*
445 *pediatrics & adolescent medicine*, 158(6), pp.531–537.
- 446 Grady, R. et al., 2012. Elective single embryo transfer and perinatal outcomes: A systematic review
447 and meta-analysis. *Fertility and Sterility*, 97(2), pp.324–331.
- 448 Halloran, B.P. & DeLuca, H.F., 1980. Effect of vitamin D deficiency on fertility and reproductive
449 capacity in the female rat. *J Nutr*, 110(8), pp.1573–1580.
- 450 Harbord, R.M., Egger, M. & Sterne, J., 2006. A modified test for small study effects in meta-analyses

451 of controlled trials with binary endpoints. *Stat. Med*, 25, pp.3443–3457.

452 Heaney, R.P., 2008. Vitamin D in health and disease. *Clinical journal of the American Society of*
453 *Nephrology : CJASN*, 3(5), pp.1535–41. Available at:
454 <http://www.ncbi.nlm.nih.gov/pubmed/18525006>.

455 Holick, M.F. et al., 2011. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine
456 Society clinical practice guideline. *The Journal of clinical endocrinology and metabolism*, 96(7),
457 pp.1911–30. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21646368>.

458 Holick, M.F., 2007. Vitamin D deficiency. *The New England journal of medicine*, 357(3), pp.266–281.
459 Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17634462>.

460 Human Fertility Embryology Authority, 2016. *Fertility Treatment 2014*,

461 Ingles, S.A., 2007. Can Diet and/or Sunlight Modify the Relationship between Vitamin D Receptor
462 Polymorphisms and Prostate Cancer Risk? *Nutrition Reviews*, 65(SUPPL.2).

463 John, E.M. et al., 2007. Sun exposure, vitamin D receptor gene polymorphisms, and breast cancer
464 risk in a multiethnic population. *American Journal of Epidemiology*, 166(12), pp.1409–1419.

465 Khalessi, N. et al., 2015. The Relationship between Maternal Vitamin D Deficiency and Low Birth
466 Weight Neonates. *Journal of family & reproductive health*, 9(3), pp.113–117. Available at:
467 [http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4662754&tool=pmcentrez&rende](http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4662754&tool=pmcentrez&render_type=abstract)
468 [rtpe=abstract\nhttp://www.ncbi.nlm.nih.gov/pubmed/26622309\nhttp://www.pubmedcentr](http://www.ncbi.nlm.nih.gov/pubmed/26622309)
469 [al.nih.gov/articlerender.fcgi?artid=PMC4662754](http://www.ncbi.nlm.nih.gov/pubmed/26622309).

470 Kinuta, K. et al., 2000. Vitamin D is an important factor in estrogen biosynthesis of both female and
471 male gonads. *Endocrinology*, 141(4), pp.1317–1324.

472 Lerchbaum, E. & Rabe, T., 2014. Vitamin D and female fertility. *Current opinion in obstetrics &*
473 *gynecology*, 26(3), pp.145–50. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24717915>.

474 Liberati, A. et al., 2009. Annals of Internal Medicine Academia and Clinic The PRISMA Statement for
475 Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care
476 Interventions : *Annals of Internal Medicine*, 151(4), pp.W65–W94.

- 477 Macklon, N.S., Geraedts, J.P.M. & Fauser, B.C.J.M., 2002. Conception to ongoing pregnancy: The
478 "black box" of early pregnancy loss. *Human Reproduction Update*, 8(4), pp.333–343.
- 479 Moher, D. et al., 2009. Reprint--preferred reporting items for systematic reviews and meta-analyses:
480 the PRISMA statement. *Physical therapy*, 89(9), pp.873–880.
- 481 Moon, R.J., Harvey, N.C. & Cooper, C., 2015. ENDOCRINOLOGY IN PREGNANCY: Influence of maternal
482 vitamin D status on obstetric outcomes and the fetal skeleton. *European Journal of*
483 *Endocrinology*, 173(2), pp.R69–R83.
- 484 National Institute for Health and Care Excellence, N., 2013. Fertility: assessment and treatment for
485 people with fertility problems. *NICE CLinical Guidelines*, (May), p.274–. Available at:
486 [http://scholar.google.com/scholar?hl=en&btnG=Search&q=intitle:Fertility+:+assessment+and+](http://scholar.google.com/scholar?hl=en&btnG=Search&q=intitle:Fertility+:+assessment+and+treatment+for+people+with+fertility+problems#0)
487 [http://scholar.google.com/scholar?hl=en&](http://scholar.google.com/scholar?hl=en&btnG=Search&q=intitle:Fertility+:+assessment+and+treatment+for+people+with+fert.)
488 [btnG=Search&q=intitle:Fertility+:+assessment+and+treatment+for+people+with+fert.](http://scholar.google.com/scholar?hl=en&btnG=Search&q=intitle:Fertility+:+assessment+and+treatment+for+people+with+fert.)
- 489 Neville, G. et al., 2016. Vitamin D status and fertility outcomes during winter among couples
490 undergoing in vitro fertilization/intracytoplasmic sperm injection. *Int J Gynaecol Obstet.*,
491 135(2), pp.172–176.
- 492 Ozkan, S. et al., 2010. Replete vitamin D stores predict reproductive success following in vitro
493 fertilization. *Fertility and Sterility*, 94(4), pp.1314–1319.
- 494 Paffoni, A. et al., 2014. Vitamin D deficiency and infertility: Insights from in vitro fertilization cycles.
495 *Journal of Clinical Endocrinology and Metabolism*, 99(11), pp.E2372–E2376.
- 496 Panda, D.K. et al., 2001. Targeted ablation of the 25-hydroxyvitamin D 1alpha -hydroxylase enzyme:
497 evidence for skeletal, reproductive, and immune dysfunction. *Proceedings of the National*
498 *Academy of Sciences of the United States of America*, 98(13), pp.7498–7503.
- 499 Robinson, C.J. et al., 2011. Maternal vitamin D and fetal growth in early-onset severe preeclampsia.
500 *American Journal of Obstetrics and Gynecology*, 204(6).
- 501 Rojansky, N., Brzezinski, A. & Schenker, J.G., 1992. Seasonality in human reproduction: an update.
502 *Human Reproduction*, 7(6), pp.735–745.

- 503 Ross, A., Manson, J. & Abrams, S., 2011. The 2011 Report on Dietary Reference Intakes for Calcium
504 and Vitamin D from the Institute of Medicine: What Clinicians Need to Know. *The Journal of*
505 *Clinical Endocrinology and Metabolism*, 96(1), pp.53–58.
- 506 Rudick, B. et al., 2012. Characterizing the influence of vitamin D levels on IVF outcomes. *Human*
507 *Reproduction*, 27(11), pp.3321–3327.
- 508 Rudick, B. et al., 2010. Characterizing the role of vitamin D levels on IVF outcomes: stimulation,
509 embryo, or endometrium? *Fertility and Sterility*, 94(4), p.S72. Available at:
510 <http://linkinghub.elsevier.com/retrieve/pii/S0015028210013853>.
- 511 Rudick, B.J. et al., 2014. Influence of vitamin D levels on in vitro fertilization outcomes in donor-
512 recipient cycles. *Fertility and Sterility*, 101(2), pp.447–452.
- 513 Schünemann, H. et al., 2011. Cochrane Handbook for Systematic Reviews of Interventions Version
514 5.1.0. In *Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0*.
- 515 Stephanou, A., Ross, R. & Handwerger, S., 1994. Regulation of Human Placental Lactogen Expression
516 by 1,25-Dihydroxyvitamin D3. *Endocrinology*, 135(6), pp.2651–2656.
- 517 Sullivan, S.S. et al., 2005. Adolescent girls in maine are at risk for vitamin D insufficiency. *Journal of*
518 *the American Dietetic Association*, 105(6), pp.971–974.
- 519 Tangpricha, V. et al., 2002. Vitamin D insufficiency among free living healthy young adults. *American*
520 *Journal of Medicine*, 112(8), pp.659–662.
- 521 Wang, O. et al., 2012. Association between vitamin D insufficiency and the risk for gestational
522 diabetes mellitus in pregnant Chinese women. *Biomedical and environmental sciences : BES*,
523 25(4), pp.399–406. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23026519>.
- 524 Wei, S.Q., 2014. Vitamin D and pregnancy outcomes. *Current opinion in obstetrics & gynecology*,
525 26(6), pp.438–47. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25310531>.
- 526 Wells, G. et al., 2011. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised
527 studies in meta-analysis. 2011. , p.http://www.ohri.ca/programs/clinical_epidemiolog.
- 528 Yoshizawa, T. et al., 1997. Mice lacking the vitamin D receptor exhibit impaired bone formation,

529 uterine hypoplasia and growth retardation after weaning. *Nature genetics*, 16(4), pp.391–396.

530 Available at:

531 <http://www.ncbi.nlm.nih.gov/pubmed/9241280>\n[http://www.nature.com/ng/journal/v16/n4/](http://www.nature.com/ng/journal/v16/n4/abs/ng0897-391.html)
532 [abs/ng0897-391.html](http://www.nature.com/ng/journal/v16/n4/abs/ng0897-391.html).

533 Zhang, M.X. et al., 2015. Vitamin D deficiency increases the risk of gestational diabetes mellitus: A

534 meta-analysis of observational studies. *Nutrients*, 7(10), pp.8366–8375. Available at:

535 [http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed13&AN=2](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed13&AN=2015431828)
536 [015431828](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed13&AN=2015431828)\n[http://sfx.ucl.ac.uk/sfx_local?sid=OVID:embase&id=pmid:&id=doi:10.3390/nu710](http://sfx.ucl.ac.uk/sfx_local?sid=OVID:embase&id=pmid:&id=doi:10.3390/nu7105398&issn=2072-6643&isbn=&volume=7&issue=10&spage=8366&pages=8366-8375&date=2015&title)
537 [538 \[8375&date=2015&title\]\(http://sfx.ucl.ac.uk/sfx_local?sid=OVID:embase&id=pmid:&id=doi:10.3390/nu7105398&issn=2072-6643&isbn=&volume=7&issue=10&spage=8366&pages=8366-8375&date=2015&title\).](http://sfx.ucl.ac.uk/sfx_local?sid=OVID:embase&id=pmid:&id=doi:10.3390/nu7105398&issn=2072-6643&isbn=&volume=7&issue=10&spage=8366&pages=8366-</p></div><div data-bbox=)

539

540

541

542 **Figure Legends**

543 Figure 1. PRISMA flow diagram for study selection.

544

545 Figure 2. Meta-analysis of studies reporting live birth by vitamin D concentrations. Meta-analysis of
546 the data from seven included studies that reported live birth as an outcome showed that women
547 who are vitamin D replete have a higher chance of achieving a live birth from ART when compared
548 with women with vitamin D deficiency or insufficiency. F-H, Fixed; Fixed effects (Mantel-Haenszel)

549

550 Figure 3. Meta-analysis of studies reporting biochemical pregnancy by vitamin D concentrations.
551 Meta-analysis of the data from five included studies that reported biochemical pregnancy as an
552 outcome showed that women who are vitamin D replete have a higher chance of achieving a
553 positive pregnancy test from ART when compared with women with vitamin D deficiency or
554 insufficiency.

555

556 Figure 4. Meta-analysis of studies reporting clinical pregnancy by vitamin D concentrations. Meta-
557 analysis of the data from all 11 of the included studies that reported clinical pregnancy as an
558 outcome showed that women who are vitamin D replete have a higher chance of achieving clinical
559 pregnancy from ART when compared with women with vitamin D deficiency or insufficiency.

560

561 Figure 5. Meta-analysis of studies reporting clinical pregnancy by vitamin D concentrations according
562 to source of oocyte. Meta-analysis of the data from nine included studies showed that women who
563 are vitamin D replete have a higher chance of achieving a clinical pregnancy from ART using
564 autologous oocytes when compared with women with vitamin D deficiency or insufficiency. Meta-
565 analysis of the data from two included studies showed no difference in the chance of clinical
566 pregnancy in women replete, insufficient or deficient in vitamin D undergoing ART using donor
567 oocytes.

Comment [RC7]: Please give a brief description interpreting the plot, so the figure stands alone without needing to refer back to the main text.

Comment [RC8]: Please give a brief description interpreting the plot, so the figure stands alone without needing to refer back to the main text.

Comment [RC9]: Please give a brief description interpreting the plot, so the figure stands alone without needing to refer back to the main text.

Comment [RC10]: Please give a brief description interpreting the plot, so the figure stands alone without needing to refer back to the main text.

568
569 Figure 6. Meta-analysis of studies reporting miscarriage by vitamin D concentrations. Meta-analysis
570 of the data from six included studies that reported miscarriage as an outcome showed no difference
571 in the chance of miscarriage in women replete, insufficient or deficient in vitamin D undergoing ART.

Comment [RC11]: Please give a brief description interpreting the plot, so the figure stands alone without needing to refer back to the main text.

572
573 Supplementary Figure S1. Vitamin D and *in vitro* fertilisation treatment clinical pregnancy outcomes
574 publication bias funnel plot. The funnel plot to test for asymmetry showed no substantial evidence
575 of publication bias.

Comment [RC12]: Please give a brief description interpreting the plot, so the figure stands alone without needing to refer back to the main text.

576
577 Supplementary Figure S2. Meta-analysis of studies reporting clinical pregnancy by vitamin D
578 concentrations implementing Institute of Medicine cut-offs. Data could be extracted from nine of
579 the included studies to compare the chances of clinical pregnancy by using the Institute of Medicine
580 definitions of vitamin D status (vitamin D concentrations of less than 50nmol/L considered as
581 deficient or insufficient and vitamin D concentrations of more than 50nmol/L considered replete).
582 Meta-analysis of the data from these nine studies showed that women who are vitamin D replete
583 have a higher chance of achieving clinical pregnancy from ART when compared with women with
584 vitamin D deficiency or insufficiency according to Institute of Medicine vitamin D cut-offs.

Comment [RC13]: Please give a brief description interpreting the plot, so the figure stands alone without needing to refer back to the main text.


Figure 1. PRISMA flow diagram for study selection.

Figure 2. Meta-analysis of studies reporting live birth by vitamin D concentrations




Figure 3. Meta-analysis of studies reporting biochemical pregnancy by vitamin D concentrations




Figure 4. Meta-analysis of studies reporting clinical pregnancy by vitamin D concentrations




Figure 5. Meta-analysis of studies reporting clinical pregnancy by vitamin D concentrations according to source of oocyte




Figure 6. Meta-analysis of studies reporting miscarriage by vitamin D concentrations




Table I. Characteristics of included studies

Author (year)	Study design	Study population	Age of study population	Bio-fluid used for vitamin D assessment	Timing of vitamin D assessment	Method of vitamin D assessment	Vitamin D cut-offs utilised	Autologous or donated oocyte	Summary of results	Confounders adjustment	Conclusions	
Anifandis et al., (2010)	Prospective Cohort	101 women undergoing IVF in Greece	Not reported	Vitamin D in follicular fluid	At oocyte retrieval	25-OH vitamin D by electrochemiluminescence immunoassay (ECLIA)	Deficiency <50nmol/L Insufficiency 50-75nmol/L Replete >75nmol/L	Autologous	<p><u>Clinical pregnancy (intrauterine sac seen 3-4 weeks on ultrasound scan post-HCG)</u> 10/31 deficient group 16/49 insufficient group 3/21 replete group</p> <p><u>Pregnancy test positive</u> Data not provided</p>	<p><u>Miscarriage</u> Data not provided</p> <p><u>Live birth</u> Data not provided</p>	Nil	Follicular fluid vitamin D concentrations significantly correlated to the quality of the embryos. Data suggested that high concentrations of vitamin D led to a decreased chance of clinical pregnancy
Fabris et al., (2014)	Retrospective Cohort	267 women undergoing donor oocyte IVF in Spain	Mean age 40.5 years	Vitamin D in serum	At oocyte retrieval	25-OH vitamin D by enzyme-linked immunosorbent assay (ELISA)	Deficiency <50nmol/L Insufficiency 50-75nmol/L Replete >75nmol/L	Donated	<p><u>Clinical pregnancy (intrauterine sac seen 5 weeks on ultrasound scan after embryo transfer)</u> 68/92 deficient group 94/134 insufficient group 29/41 replete group</p> <p><u>Pregnancy test positive (pregnancy test positive 2 weeks after embryo transfer)</u> 60/92 deficient group 85/134 insufficient group 25/41 replete group</p>	<p><u>Miscarriage (pregnancy loss after clinical pregnancy achieved)</u> 8/92 deficient group 9/134 insufficient group 4/41 replete group</p> <p><u>Live birth</u> 56/92 deficient group 71/134 insufficient group 23/41 replete group</p>	Nil	No significant difference in implantation or clinical pregnancy rates between deficient, insufficient and replete vitamin D groups
Firouzabadi et al., (2014)	Prospective Cohort	221 women undergoing IVF in Iran	Mean age 29.2 years	Vitamin D in follicular fluid and serum	At oocyte retrieval	25-OH vitamin D by enzyme-linked immunosorbent assay (ELISA)	Deficiency <25nmol/L Insufficiency 25-75nmol/L Replete >75nmol/L	Autologous	<p><u>Clinical pregnancy (intrauterine sac seen on ultrasound scan [no time point defined])</u> 23/50 deficient group 47/155 insufficient group 4/16 replete group</p> <p><u>Pregnancy test positive</u> Data not provided</p>	<p><u>Miscarriage</u> Data not provided</p> <p><u>Live birth</u> Data not provided</p>	Nil	No significant correlation between follicular fluid or serum vitamin D and clinical pregnancy rate. Significant correlation between follicular fluid vitamin D concentrations and serum vitamin D concentrations

Franasiak et al., (2015)	Retrospective cohort	517 women undergoing IVF with euploid blastocyst transfer in USA	Mean age 35.0 years	Vitamin D in serum	At ovulation trigger injection	25-OH vitamin D by enzyme-linked immunosorbent assay (ELISA)	Deficiency <50nmol/L Insufficiency 50-75nmol/L Replete >75nmol/L	Autologous	<u>Clinical pregnancy (intrauterine sac seen on ultrasound scan [no time point defined])</u> 144/206 deficient group 151/215 insufficient group 64/96 replete group <u>Pregnancy test positive (pregnancy test positive 2 weeks after embryo transfer)</u> 163/206 deficient group 162/215 insufficient group 74/96 replete group	<u>Miscarriage (pregnancy loss after positive pregnancy test but before intrauterine gestational sac seen or pregnancy loss after gestational sac seen)</u> 32/206 deficient group 29/215 insufficient group 14/96 replete group <u>Live birth</u> 131/206 deficient group 133/215 insufficient group 60/96 replete group	Adjustment for age, BMI, ethnicity, season, number of previous treatment cycles, number of embryos transferred	Vitamin D status unrelated to pregnancy rates in women undergoing euploid blastocyst transfers
Fru et al., (2014)	Retrospective Cohort	102 women undergoing IVF in USA	Not reported	Vitamin D in serum	Pre-cycle but not defined	25-OH vitamin D Method not defined	Deficiency <50nmol/L Insufficiency 50-75nmol/L Replete >75nmol/L	Autologous	<u>Clinical pregnancy (not defined)</u> 6/18 deficient group 24/47 insufficient group 37/58 replete group <u>Pregnancy test positive</u> Data not provided	<u>Miscarriage (not defined)</u> 1/6 deficient group 9/24 insufficient group 12/37 replete group <u>Live birth</u> 5/18 deficient group 15/47 insufficient group 25/58 replete group	Nil	Higher vitamin D concentrations correlated with increased likelihood of positive pregnancy test. Overall live birth rates highest in vitamin D replete group.
Garbedian et al., (2013)	Prospective Cohort	173 women undergoing IVF in Canada	Mean age 34.5 years	Vitamin D in serum	Before oocyte retrieval	25-OH vitamin D Method not defined	Deficiency and insufficiency <75nmol/L Replete >75nmol/L	Autologous	<u>Clinical pregnancy (intrauterine sac seen on ultrasound scan [no time point defined])</u> 33/95 deficient and insufficient groups combined 41/78 replete group <u>Pregnancy test positive</u> Data not provided	<u>Miscarriage</u> Data not provided <u>Live birth</u> Data not provided	Adjustment for age, BMI, number of embryos transferred and vitamin D concentration	Implantation and clinical pregnancy rates are higher in the vitamin D sufficient group (>75nmol/L). Statistical significant difference in clinical pregnancy rate, no statistical difference in pregnancy positive rate.
Ozkan et al., (2010)	Prospective Cohort	84 women undergoing IVF in Turkey	Mean age 34.4 years	Vitamin D in follicular fluid and serum	At ovulation trigger injection	25-OH vitamin D Method not defined	Deficiency <50nmol/L Insufficiency	Autologous	<u>Clinical pregnancy (intrauterine sac seen on ultrasound scan [no time point defined])</u> 5/23 deficient group 6/30 insufficient group	<u>Miscarriage</u> Data not provided <u>Live birth</u>	Adjustment for age, BMI, ethnicity, number of embryos transferred and vitamin D concentration	Serum and follicular fluid strong correlated. Higher implantation and clinical pregnancy rates in insufficient (20-30ng/ml) and


							ency 50- 75nmol/ L Replete >75nmol/ L		15/31 replete group <u>Pregnancy test positive (pregnancy test positive 2 weeks after embryo transfer)</u> 3/23 deficient group 4/30 insufficient group 8/31 replete group	Data not provided		replete concentrations (>30ng/ml) when compared to deficient group - highest in replete group.
Paffoni et al.,(2014)	Prospective cohort	335 women undergoing IVF in Italy	Mean age 36.9 years	Vitamin D in serum	Pre-cycle but not defined	25-OH vitamin D by electrochemiluminescence immunoassay (ECLIA)	Deficiency <50nmol/L Insufficiency 50-75nmol/L Replete >75nmol/L	Autologous	<u>Clinical pregnancy (intrauterine sac seen on ultrasound scan [no time point defined])</u> 30/154 deficient group 33/117 insufficient group 23/64 replete group <u>Pregnancy test positive (pregnancy test positive 2 weeks after embryo transfer)</u> 34/154 deficient group 36/117 insufficient group 25/64 replete group	<u>Miscarriage</u> Data not provided <u>Live birth</u> 29/154 deficient group 19/117 insufficient group 19/64 replete group	Nil	Analysis suggested those with a vitamin D >75nmol/L had the highest chance of clinical pregnancy when compared with those with vitamin D deficiency or insufficiency.
Polyzos et al., (2014)	Retrospective cohort	368 women undergoing IVF resulting in single blastocyst embryo transfer in Belgium	Mean age 30.6 years	Vitamin D in serum	At ovulation trigger injection	25-OH vitamin D by enzyme-linked immunosorbent assay (ELISA)	Deficiency <50nmol/L Insufficiency 50-75nmol/L Replete >75nmol/L	Autologous	<u>Clinical pregnancy (intrauterine sac seen 5 weeks on ultrasound scan after embryo transfer)</u> 98/239 deficient group 70/129 insufficient and replete group combined <u>Pregnancy test positive (pregnancy test positive 2 weeks after embryo transfer)</u> 124/239 deficient group 86/129 insufficient and replete groups combined	<u>Miscarriage (pregnancy loss after positive pregnancy test but before intrauterine gestational sac seen or pregnancy loss after gestational sac seen)</u> 44/239 deficient group 25/129 insufficient and replete groups combined <u>Live birth</u> 78/239 deficient group 61/129 insufficient and replete groups combined	Adjustment for age, number of previous treatment cycles, type of treatment protocol. Type of gonadotrophin used, starting dose of gonadotrophin, E2 levels on day of HCG, number of oocytes collected, type of treatment, day 5 embryo transfer, top quality embryo transfer, endometrial thickness, serum progesterone at trigger injection, season and vitamin D concentration	Clinical pregnancy rate significantly lower in vitamin D deficient group p=0.015. Controlled for 16 confounding factors.

Rudick et al., (2012)	Retrospective cohort	188 women undergoing IVF in USA	Mean age 36.0 years	Vitamin D in serum	Pre-cycle but not defined	25-OH vitamin D by enzyme-linked immunosorbent assay (ELISA)	Deficiency <50nmol/L Insufficiency 50-75nmol/L Replete >75nmol/L	Autologous	<u>Clinical pregnancy (intrauterine sac seen 5 weeks on ultrasound scan after embryo transfer)</u> 14/39 deficient group 29/70 insufficient group 34/79 replete group <u>Pregnancy test positive</u> Data not provided	<u>Miscarriage (pregnancy loss after positive pregnancy test but before intrauterine gestational sac seen or pregnancy loss after gestational sac seen)</u> 3/39 deficient group 7/70 insufficient group 8/79 replete group <u>Live birth</u> 11/39 deficient group 22/70 insufficient group 26/79 replete group	Adjustment for age, number of embryos transferred, embryo quality, and diagnosis of diminished ovarian reserve	Vitamin D deficiency associated with lower CPR in non-hispanic whites but not in Asians
Rudick et al., (2014)	Retrospective cohort	99 women undergoing donor oocyte IVF in USA	Mean age 40.9 years Range 21-39	Vitamin D in serum	Pre-cycle but not defined	25-OH vitamin D by enzyme-linked immunosorbent assay (ELISA)	Deficiency <50nmol/L Insufficiency 50-75nmol/L Replete >75nmol/L	Donated	<u>Clinical pregnancy (intrauterine sac seen 5 weeks on ultrasound scan after embryo transfer)</u> 9/26 deficient group 16/38 insufficient group 26/35 replete group <u>Pregnancy test positive</u> Data not provided	<u>Miscarriage (pregnancy loss after positive pregnancy test but before intrauterine gestational sac seen or pregnancy loss after gestational sac seen)</u> 1/26 deficient group 3/38 insufficient group 6/35 replete group <u>Live birth</u> 8/26 deficient group 13/38 insufficient group 20/35 replete group	Adjustment for embryo quality, BMI and ethnicity	Lower CPRs in those with vitamin D deficiency suggesting that the effects are localised within the endometrium


Table II. Newcastle-Ottawa Scale appraisal of included studies

Study	Case representative	Control representative	Ascertainment of exposure	Outcome negative at start	Comparability by design or analysis	Outcome assessment	Duration of follow up	Adequacy of follow up	Score
Anifandis et al., (2010)	*	*	*	*	**	*	*	x	8
Fabris et al., (2014)	*	*	*	*	*	*	*	*	8
Firouzabadi et al., (2014)	*	*	*	*	x	*	*	*	7
Franasiak et al., (2015)	*	*	*	*	*	*	*	*	8
Fru et al., (2014)	*	*	*	*	x	*	*	*	7
Garbedian et al., (2013)	*	*	*	*	*	*	*	*	8
Ozkan et al., (2010)	*	*	*	*	**	*	*	*	9
Paffoni et al., (2014)	*	*	*	*	*	*	*	*	8
Polyzos et al., (2014)	*	*	*	*	**	*	*	*	9
Rudick et al., (2012)	*	*	*	*	x	*	*	*	7
Rudick et al., (2014)	*	*	*	*	**	*	*	*	9

Supplementary Figure S1. Vitamin D and in vitro fertilisation treatment clinical pregnancy outcomes publication bias funnel plot



Supplementary Figure S2. Meta-analysis of studies reporting clinical pregnancy by vitamin D concentrations implementing Institute of Medicine cut-offs



Supplementary Table S1**Full electronic search strategy: Vitamin D and Assisted Reproductive Treatment Outcomes**

Line	Database	Search term
1	Medline	"pregnancy".ti,ab
2	Medline	"in vitro fertilisation".ti,ab
3	Medline	"intracytoplasmic sperm injection".ti,ab
4	Medline	"assisted reproductive treatment".ti,ab
5	Medline	1 OR 2 OR 3 OR 4
6	Medline	VITAMIN D/
7	Medline	((vitamin ADJ D)).ti,ab
8	Medline	((cholecalciferol OR ergocalciferol)).ti,ab
9	Medline	6 OR 7 OR 8
10	Medline	5 AND 9

ti; title, ab; abstract, ADJ; adjacent



PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	Page 1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	Page 3 to 4
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	Page 5 to 7
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	Page 7
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	Not registered
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	Page 7
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	Page 7
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	Supplementary File S1
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	Page 8
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	Page 8
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	Page 7
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	Page 8 to 9
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	Page 7 to 9
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	Page 9



PRISMA 2009 Checklist

Page 1 of 2

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	Page 9 and supplementary file S2
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	Page 7 to 9
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	Page 9 and figure 1
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	Page 10 and table 1
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	Page 11, supplementary file S2 and table 1
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	Page 11 to 13, Figures 2 to 6 and Table 1
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	Page 11 to 13 and Figures 2 to 6
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	Page 11 and supplementary file S2
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	Page 12 to 13, Figure 5 and supplementary file S3
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	Page 13-14



PRISMA 2009 Checklist

Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	Page 14
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	Page 14 to 17
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	Page 18

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.

Page 2 of 2